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MODULATION OF THE HUMORAL IMMUNE RESPONSE BY THE 
SYMPATHETIC NERVOUS SYSTEM 
ABSTRACT 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at the Medical College of Virginia/Virginia Commonwealth University 
Tracey Lynn Spriggs, Ph.D. 
Medical College of Virginia - Virginia Commonwealth University, 1994 
Advisor: Dr. Bruce A. Fuchs, Ph.D. 
The immune system is critical for the maintenance of homeostasis. Due to the 
fact that a coordinated effort between organ systems is required for internal stability, it 
has been postulated that the immune system interacts with the neuroendocrine system. 
Clinical, anatomical, and receptor studies have provided evidence for a bi-directional 
communication between the nervous and immune systems. The goal of the present 
studies was to determine the potential influence of the sympathetic nervous system 
(SNS) on the primary antibody forming cell (AFC) response. 
The adrenergic neurotoxin, 6-hydroxydopamine (6-OHDA), has been utilized 
extensively by researchers to explore the possible relationship between SNS and the 
antibody response. However, the literature describing the humoral effects observed 
following 6-OHDA treatment is irresolute. In an attempt to provide insight into these 
apparent discrepancies, studies were conducted comparing the effects of 6-OHDA and its 
non-neurotoxic congener, 5-hydroxydopamine (5-OHDA). Both chemicals, when added 
directly into cultures containing naive splenocytes, suppressed the in vitro AFC 
response. Analysis following in vivo treatment with 6-OHDA or 5-OHDA revealed that 
XVll 
while both chemical treatments resulted in suppression of the AFC response following in 
vivo sensitization, only the splenocytes from 6-0HDA treated mice were suppressed 
when subsequently sensitized in vitro. Pretreatment with desmethylimipramine (DMI) 
blocked the observed 6-0HDA- and 5-0HDA-induced immunosuppression displayed in 
vivo, indicating that the uptake of the chemicals into adrenergic neurons was required. 
As an alternative method for removing the sympathetic influence in the spleen, studies 
were conducted with chlorisondamine, a non-competitive ganglionic blocker. While 
direct addition of chlorisondamine was without effect in the in vitro-in vitro AFC 
response, the in vivo AFC response following chlorisondamine treatment was 
significantly suppressed. 
In addition to the suppression of the primary AFC response, 6-0HDA and 
chlorisondamine treatment resulted in a time dependent increase in the level of DNA 
fragmentation in the thymus. Analysis of serum corticosterone levels in 6-0HDA- and 
chlorisondamine-treated mice revealed that both treatments elevated levels of serum 
corticosterone. Given the potential role of corticosterone in the 6-0HDA- and 
chlorisondamine-induced immunosuppression, studies were conducted to determine if 
the glucocorticoid receptor antagonist, RU-486, was able to block the DNA 
fragmentation in the thymus and the suppression of the AFC response demonstrated after 
6-0HDA or chlorisondamine treatment. While RU-486 was effective at blocking the 6-
0HDA- and chlorisondamine-induced thymic effects, it was unable to block the 
suppression of the primary AFC response. Collectively, these studies reveal that 
removal of the peripheral SNS by either sympathectomy with 6-0HDA or ganglionic 
blockade with chlorisondamine can result in 1) thymic alterations which are mediated by 
increased levels of corticosterone and 2) suppression of the primary AFC response which 
is independent of the elevated corticosterone levels. Importantly, these results provide 
evidence for positive modulation of the humoral immune response by the sympathetic 
nervous system. 
INTRODUCTION 
The potential interactions existing between the neuroendocrine system and the 
immune system have been extensively explored over the past two decades. Historically, 
the immune system has been viewed as autonomous, requiring only the function of its 
cells and mediators to produce an adaptive response to antigen. The immune system is a 
critical organ system required to maintain homeostasis. Given that homeostasis is the 
maintenance of internal stability through the coordinated efforts of various organ systems, 
it might be expected that bi-directional communications would exist between the central 
nervous system, endocrine system and immune system (Figure 1). 
The roots of neuroimmunomodulation (NIM) date back to Mechnikov ( 1845-
1916) and the neurogenic theory in biomedical sciences proposed by the Russian 
scientists Sechenov, Botkin, and Pavlov (Corson and Corson, 1988). Presently, there is a 
growing body of evidence which indicates that there are indeed interactions between the 
immune system and the neuroendocrine system (Besedovsky et al. , 1985; Solomon, 
1987; Rabin et al. , 1989; Besedovsky and Del Rey, 1992). This research has provided 
clinical, anatomical, and functional evidence for a bi-directional communication. 
However, this field of scientific discovery is, by modem standards, still in its infancy. 
The literature is both extensive and exceedingly complex due to the fact that NIM 
incorporates the three scientific disciplines of neuroscience, endocrinology and 
immunology. 
1 
I Central Nervous System I 
I Endocrine System I .. .. I Immune System I 
Figure 1 .  The neuro-endocrine-immune triad. 
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The bi-directional communication between the immune and neuroendocrine 
systems involves both afferent and efferent regulatory pathways. The afferent signals are 
those factors produced by immunocompetent cells which communicate to the 
neuroendocrine system that the immune system is responding to an antigen. One key 
factor mediating this interaction is the cytokine, interleukin 1 (IL-1). IL-1 is produced by 
activated macrophages, as well as other cells, and produces profound effects both in the 
immune system and in the central nervous system (Dinarello, 1988). 
\ 
The efferent signals between the central nervous system and immune system 
originate in the neuroendocrine system and function to alter the immune response. The 
mechanisms through which this type of communication is possible involves a complex 
network of soluble messengers and receptors (Roszman and Brooks, 1988) and direct 
innervation of immune organs (Felten et al. , 1985). A major regulatory loop mediating 
this communication is the hypothalamic-pituitary-adrenal (HPA) axis. The hormones 
comprising the HPA axis, namely corticotropin-releasing factor (CRF) and 
glucocorticoids, have been demonstrated to directly modulate immune function. 
The second regulatory pathway which mediates efferent signals is the sympathetic 
nervous system (SNS). The interaction between the SNS and the immune system has 
been the subject of numerous investigations. Nevertheless, the literature assessing 
alterations in immune function following sympathectomy with the adrenergic neurotoxin, 
6-hydroxydopamine (6-0HDA), has not provided a clear delineation of the relationship 
between the SNS and immune system. The goal of the studies presented in this 
dissertation is to provide further insight into the nature of the regulation between these 
two systems. The results generated from these investigations 1) help to clarify the 
apparent discrepancies in the 6-0HDA literature; 2) demonstrate that activation of the 
HPA axis can be a direct result of sympathectomy and; 3) provide further support for a 
positive modulatory role of the SNS on the humoral immune response. 
LITERATURE REVIEW 
The Immune System 
The essential function of the immune system is to provide protection from 
pathogens and eliminate foreign antigens. This system, which can be divided into the 
innate and adaptive immune systems, is composed of specialized cells and soluble 
mediators. A key feature of the immune system is to maintain a critical balance of 
responding to non-self antigens while not responding to self. In the event that the 
immune system is unable to maintain this balance, the consequence to the organism will 
either be one of pathogen induced disease or of autoimmunity. 
Innate immunity, one of the two functional divisions of the immune system, 
serves as the first line of defense against invading organisms. This defense is comprised 
of non-specific biochemical and physical barriers (the skin, cilia, mucus membranes, and 
lysozyme). The cells and other mediators which characterize the innate immune system 
include phagocytes, natural killer (NK) cells, acute phase proteins, and complement. In 
contrast to adaptive immunity, innate immunity lacks immunological memory. 
Adaptive immunity is an antigen driven response mediated by cells derived from 
the thymus (T-lymphocytes) and cells derived from the bone marrow (B-lymphocytes). 
This division of the immune system can be further subdivided into cell-mediated 
immunity and humoral immunity. Cell mediated immunity and humoral immunity both 
require the function of antigen processing cells (APC). The macrophage is a primary 
APC which secretes Interleukin- I (IL- 1 )  and serves as the initial activator for both cell 
4 
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mediated and humoral immune responses. One of the functions of the macrophage is to 
process and present antigen on its surface (Johnston, 1988). This process is carried out 
in a genetically restricted manner (Mosier, 1967) whereby the antigen is presented in 
association with a gene-encoded product, the class Il Major Histocompatibility Complex 
(MHC). The T-helper (f H) lymphocyte is activated through this antigen presentation 
process and is subsequently induced to proliferate through the secretion of macrophage­
derived IL-1. Cell mediated immune responses involve the activation of a specific 
subset of T-helper cells, the T-helper 1 lymphocyte (fHl ). The most recently identified 
cytokine secreted from macrophages, IL-12, has been determined to be a key regulator of 
the activation of TH 1 lymphocytes (Scott, 1993). Following activation, the THl 
lymphocyte will secrete IL-2 and y-interferon to up-regulate the function of T-cytolytic 
(fCJL) or T-delayed type hypersensitivity (ToTH) lymphocytes. The TCIL and ToTH 
lymphocytes require the presence of class I MHC antigens and mediate immune 
responses such as graft rejection, delayed hypersensitivity and yeast, fungal and viral 
infections. Whereas cell mediated immunity results in an antigen-specific response 
mediated by specific immunocytes, humoral immunity is characterized by an antigen 
specific response mediated by specific effector molecules known as antibodies. The B­
lymphocyte is a critical cell type mediating humoral immune responses. The type of 
antigen which is involved in humoral immunity will ultimately determine the course of 
the antibody response and is discussed further in the following section. Immunological 
memory is a key element in both cell mediated immunity and humoral immunity. 
The Antibody Respome 
The production of antibody is a humoral immune response to a specific antigen. 
Precursor B-lymphocytes undergo an antigen independent maturation process whereby 
they express specific receptors for antigen on their cell surface. These receptors on the B 
6 
cell surface are antibody molecules which are composed of two heavy and two light 
chains. The variable region on the end of the antibody molecule binds specific antigen 
The incredible ability of antibodies to recognize an infinite number of antigens was 
originally proposed by Paul Ehrlich (1854-1915), a pioneer in the scientific disciplines of 
immunology and pharmacology. 
Antigens such as TNP-Ficoll are classified as T-independent antigens and do not 
require the TH lymphocyte for B-lymphocyte activation. The T-independent antigens are 
characterized as being polymeric and resistant to degradation (Roitt et al. , 1989). An 
antibody response produced against a T-dependent antigen such as sheep red blood cells 
(sRBC), requires the function of macrophages, B-lymphocytes, and TH-lymphocytes. 
The initial activation of the B-lymphocyte requires the action of T-helper 2 (TH2) 
lymphocytes (Noelle et al. ,  1983) in addition to the macrophage. The B lymphocyte 
with its surface immunoglobulin (lg), and the TH2 lymphocyte with its T cell receptor 
(TCR), will bind antigen and become activated. The B-lymphocyte, through various 
signals and interaction with the TH lymphocyte (reviewed by Noelle and Snow, 1991) 
subsequently differentiates and proliferates in an antigen specific manner to become an 
antibody-secreting plasma cell. The secretion of the lymphokines IL-1, IL-2, IL-4, Il.,-5, 
and IL-6 from macrophages and TH lymphocytes is required for the production of 
antibody. Each interleukin functions at a specific stage(s) during antibody synthesis. 
Depicted in Figure 2 are the cellular interactions involved in the production of antibody. 
The primary antibody forming cell (AFC) response occurs following an initial 
exposure to antigen and leads to the proliferation and differentiation of a population of 
effector IgM-secreting B lymphocytes and a population of memory B-lymphocytes. A 
subsequent exposure to the same antigen will produce a secondary AFC response which 
is mediated by the population of memory B-lymphocytes produced with the initial 
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exposure to antigen. The secondary AFC response, which is produced by IgG secreting 
B-lymphocytes, is the fundamental principal behind vaccination. This response is 
mediated by the clonal expansion of antigen-specific memory B cells and requires less 
time for activation, is greater in capacity, and persists for a longer amount of time. The 
lymph node-derived follicular dendritic cells appear to be an important element in the 
generation of secondary immune responses and the maintenance of immunological 
memory (Tew and Mandel, 1978; Gray et al. , 1990). 
Thymic Regulation 
The thymus is a primary immune organ which is responsible for the education of 
T-lymphocytes. Prothymocytes are seeded from the bone marrow and travel through the 
circulation to the thymus. As the prothymocytes matures, it will progress from an 
immature CD4+/CD8+ thymocyte and lose one or the other surface proteins to become 
either a CD4+ (T-helper) or CD8+(T-suppressor/cytotoxic) thymocyte. 
The thymus is composed of cortical and medullary portions. Following 
maturation, thymocytes relocate from the cortex to the medulla region. Analogous to the 
antibody receptors on B lymphocytes, the TCR also has the ability to recognize an 
infinite number of foreign antigens. The education of thymocytes is a process which 
functions to produce a diverse repertoire of TCR which have the ability to recognize both 
self and non-self antigens. The thymic cortical epithelial cells, thymocyte TCR, and 
class I MHC molecules are all important in this educational process. However, the TCR 
is the ultimate factor which determines the fate of the individual thymocyte (Blackman et 
al. , 1 990). Those thymocytes which display an adequate affinity for self antigens (class I 
MHC) undergo a positive selection process, whereas those thymocytes which bear self­
reactive T-cell receptors are deleted by negative selection. 
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The clonal deletion of thymocytes is the mechanism which produces T-cell 
tolerance in the immune system. Thymocytes are deleted by the physiological process 
known as apoptosis (recently reviewed by Cohen and Duke, 1992). This process, which 
is a form of programmed cell death, is schematically represented in Figure 3. In addition 
to the deletion of self-reactive thymocytes, apoptosis is involved with other processes 
such as embryonic development and cell killing in the immune system mediated by T­
cytotoxic cells and natural killer cells (Cohen, 1993). Apoptosis is also the mechanism 
through which glucocorticoids induce lymphocytolysis (Wyllie and Morris, 1982; 
Compton and Cidlowski, 1986). Once a specific signal is imparted to the cell, a calcium­
dependent endonuclease is activated and leads to the subsequent fragmentation of 
nuclear DNA and the formation of apoptotic bodies. The Ca2+ ion and protein kinase A 
signals which induce this process are inhibited by protein kinase C (McConkey et al. , 
1990). The apoptotic process specifically leads to the destruction of the cell nucleus 
without altering additional organelles in the cell. Cell death attributed to apoptosis is 
distinct from cell death due to necrosis (Fawthrop et al., 1991). The process of necrosis 
results from severe injury to the cell and is characterized by mitochondrial changes and 
cell rupture. 
Afferent Links Between the Immune and Neuroendocrine Syste� 
Immunocytes have been reported to produce a number of neuroendocrine 
hormones (reviewed by Blalock et al., 1985). The cytokine IL-1 has clearly been proven 
to be an important link between the neuroendocrine system and the immune system. IL-
1 is a multifunctional cytokine which can modulate numerous organ systems. The 
biological responses evoked by IL-1 encompass neurologic, metabolic, and 
endocrinologic mediated events. In addition to the regulation of the immune response 
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Figure 3. Mechanism of apoptosis. (Adapted from: Gerschenson, L.E. and Rotello, R.J. ( 1992) FASEB J. 6(7), 2450-2455). 
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this cytokine (also known as endogenous pyrogen) plays an important regulatory role in 
fever induction, slow wave sleep, and appetite control (Dinarello, 1988). 
Numerous studies have been conducted to determine the mechanism through 
which IL- 1 can regulate responses in the neuroendocrine system. Besedovsky and 
coworkers ( 1986) demonstrated that IL- 1 induced an increase in adrenocorticotropin 
hormone (ACTH) as well as corticosterone, thereby indicating that this cytokine may 
directly activate the hypothalamic-pituitary-adrenal (HPA) axis. This same study also 
showed that the increased level of corticosterone that accompanied a viral infection was 
blocked by prior administration with anti-IL-1 .  Although the closely related cytokines 
IL-6 and tumor necrosis factor (fNF) are also capable of stimulating the HPA axis, IL-1 
has been proven to be more potent and persistent (Besedovsky et al., 199 1 ). 
There are conflicting reports as to whether or not IL- 1 has a direct affect on the 
adrenal cortex. Roh and coworkers ( 1987) demonstrated that IL- 1 directly stimulates the 
release of corticosterone which was mediated by prostaglandin synthesis, while other 
studies demonstrated that IL- 1 did not stimulate corticosterone release from 
adrenocortical cultures (Woloski et al. , 1985; Gwosdow et al., 1990). Evidence that IL- 1 
was functioning at the level of the hypothalamus was provided by Gwosdow and 
colleagues ( 1990) who demonstrated that ACTH released from the pituitary was required 
since the IL- I-induced increase in corticosterone was abrogated in hypophysectomized 
animals. This link between IL- 1 and the HP A axis was further strengthened by 
Berkenbosch and colleagues ( 1987) who determined that corticotropin-releasing factor 
(CRF) was responsible for mediating the IL-I -induced activation of the pituitary-adrenal 
axis. Sundar and colleagues ( 1990) determined that suppression of immune function 
mediated by IL-1 was a result of CRF-induced stimulation of both the HPA axis and the 
SNS. A recent study conducted by Saito and coworkers ( 1991 )  confirmed that IL- 1 -
induced immunosuppression was mediated in part by the sympathetic nervous system 
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since removal of the peripheral sympathetic nervous system (SNS), with either the 
adrenergic neurotoxin 6-hydroxydopamine, or the ganglionic blocker chlorisondamine, 
blocked IL-I-induced leukocytosis. 
The IL- I-induced increase in corticosterone has been demonstrated to decrease 
NK activity, T lymphocyte mitogenesis, and IL-2 production (Sundar et al. , 1990). An 
interesting relationship between this cytokine and glucocorticoids has been demonstrated 
whereby IL-1 appeared to synergize with corticosterone to increase the density of J3-
adrenergic receptors on human tumor cells in vitro (Stem and Kunos, 1988; Nakane et 
al. , 1990). Glucocorticoids have previously been reported to prevent J3-adrenergic 
receptor desensitization and thereby increase J3-adrenergic receptor density in vivo 
(Salonen, 1985). 
In addition to IL-1, immunocompetent cells produce a wide array of soluble 
products which mediate various immune functions. These immunoregulatory proteins 
have been demonstrated to modulate a number of functions in the central nervous system 
(reviewed by Plata-Salaman, 1991). Furthermore, immunocytes have been reported to 
produce a number of neuroendocrine hormones. T-lymphocytes have been demonstrated 
to produce CRF, ACI'H, J3-endorphin, and thyrotropin (TSH), while other immunocytes 
produce growth hormone (GH), chorionic gonadotropin (CG), vasoactive intestinal 
peptide (VIP), somatostatin and substance P (reviewed by Blalock et al., 1988; Goetzl et 
al., 1990). 
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Efferent Links Between the Immune and Neuroendocrine Systems 
lmmunoregulatory mediators 
A number of investigators have explored the potential immunoregulatory role of 
various soluble mediators derived from the neuroendocrine system. Jackson and 
coworkers (1988) demonstrated that the neurotransmitter serotonin suppresses the in vivo 
antibody response to sRBC. Studies conducted by Devoino and colleagues (1988) 
confirm the inhibitory influence of serotonin and provide evidence that the 
neurotransmitter dopamine enhances immune responsiveness. Cholinergic agonists have 
also been demonstrated to have an immunoenhancing effect on the in vitro antibody 
response (Komeva et al. , 1988). 
The immunoenhancing effects of melatonin has been recently reviewed by 
Maestroni (1993). This hormone, which is secreted by the pineal gland, has been 
demonstrated to enhance the T-dependent primary antibody production and prevented 
stress-induced suppression of this humoral immune response (Maestroni et al., 1988). 
The hormones prolactin, somatostatin, substance P, and growth hormone have been 
reported to increase immune responsiveness, while �-endorphin, ACTH, and gonadal 
hormones have been reported to both increase and decrease the function of the immune 
system (reviewed by Kemeny et al., 1992). 
In addition to the central nervous system activating the immune system through 
the production and release of neurotransmitters and endocrine hormones, there is a 
growing body of evidence which reveals that specific cell types located in the brain are 
capable of producing cytokines (reviewed by Goetzl et al. , 1990). The cytokines IL-1, 
IL-3, IL-6, TNF, IFN and GM-CSF have been identified as being produced from either 
astrocytes or glioblastoma cells. These neural sources of soluble mediators provides 
another important link between the immune and neuroendocrine systems. Furthermore, 
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there appears to be a striking similarity between astrocytes and macrophages, including 
IL- 1 and prostaglandin E production and presentation of antigen to T lymphocytes 
(Cotman et al. , 1987). 
The Hypothalamic-Pituitary-Adrenal (HP A) Axis 
A key feature in the cross regulation between the sympathetic nervous system 
(SNS) and the immune system is the HPA axis (reviewed by Bateman et al. , 1 989; 
Goetzl and Sreedharan, 1 992). Activation of the HPA axis ultimately leads to the 
production and release of glucocorticoids. Besedovsky ( 1975) has demonstrated that the 
levels of glucocorticoids are increased during the peak immune response, thereby 
implicating a role for the HP A axis in immune regulation. Indeed, certain models of 
autoimmune disease have been demonstrated to be linked with a dysfunction in the HP A 
axis (Sternberg et al. , 1990). The thymus also appears to be a link between the immune 
system and the neuroendocrine system, as it has been demonstrated that this lymphoid 
organ can modulate the HPA axis (Pierpaoli and Besedovsky, 1975). 
The essential role of the hypothalamic-derived hormone, CRF, has been 
investigated by numerous research groups. In addition to regulating the release of 
ACfH from the pituitary, CRF stimulates the release of circulating levels of epinephrine 
and norepinephrine and functions as a key regulator of the sympathetic nervous system 
(Brown et al. ,  1982; Fisher and Brown, 1984; Brown and Fisher, 1985). Researchers 
have also discovered that CRF is a mediator of interactions between the immune and 
neuroendocrine system. Uehara and colleagues ( 1987) demonstrated that the presence of 
CRF was re.quired for IL- 1 induced release of AC1H from the pituitary. CRF has been 
demonstrated to alter immune function by suppressing both cell mediated and humoral 
immunity. Sundar and coworkers ( 1990) demonstrated that the suppression of the 
cellular immune response following IL- 1 administration was blocked by utilizing an 
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antibo dy to CRF. Irwin and colleagues (1990) demo nstrated that CRF-induced 
suppression of natural kille r cell acti vity was prevented by prior sympathectomy, thereby 
providing e vidence of a potential role for the SNS in mediating CRF-induced alte rations 
in  immune function. Recent evide nce revealed that CRF-induced immune su ppression 
can result fro m a direct effect of this hormone on  immunocompetent cells. A study 
conducted by  Leu and Singh (1993) demonst rated that the addition of CRF suppressed 
the in vitro production  of antibody. 
Acti vation  of t he HPA axis can result fro m  "stressful" e vents. Stress is a 
subjecti ve phenomenon  w he reby envi ronmental, biolo gical, physical, o r  behavio ral 
ele me nts pro duce an alte ratio n in  homeostasis. Sel ye ( 1946) c haracte ri zed the 
modulation of adrenal ste roi ds levels by  st ressful e vents as a " ge neral adaptatio n 
syndrome". Stress-i nduced alte ratio ns in  mice inclu de dec reases in  thymic wei ght, 
splenic weight and peripheral blood leukocyte number (Marsh and Rasmussen, 1960). In 
animal models, st ress produces both a suppression and an  e nhancement of the in vivo 
generated antibody response (Okimura et al., 1986), suppression of the in vitro generated 
antibody response (Gisle r, et al. , 1971 ), and su ppressio n of pe ri phe ral blood T­
ly mphocyte mitogenesis (Cunnick, et al 1990). Inte resti ngl y, a study conducted b y  
Kelle r and colleagues (1983) demonst rated that stress-i nduced su ppression  of T­
lymphocyte proliferation  was not mediated by products of adrenal sec retion. Although 
the majority of studies characterize the effects of stress as immunosuppressive, exe rcise­
i nduced stress i n  hu mans has bee n re po rted to i nc rease the po pulation of T­
suppressor/cytotoxic and NK cells (Murray, et al., 1992). 
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Gluoocorticoids 
Glucocorticoids are one of the end products of HPA activation and are 
endogenous regulators of various internal processes (Munck et al., 1984). These 
hormones are required for normal biological functions and are involved in the regulation 
of carbohydrate, protein, and lipid metabolism. Given the fact that research has 
demonstrated corticosteroid-induced immune modulation in animals (Parrillo and Fauci, 
1979) and humans (Cupps and Fauci, 1982), these hormones are an important efferent 
signal between the neuroendocrine system and the immune system. Following antigenic 
challenge, the levels of corticoids are elevated during the peak of the immune response 
(Besedovsky et al., 1975). Besedovsky and Sorkin (1977) have proposed that this 
increase in glucocorticoids is a mechanism of immunoregulation whereby antigen non­
specific lymphocytes are prevented from proliferating. Research conducted by 
Besedovsky and colleagues ( 1981) has provided insight into a possible mechanism 
responsible for the increased levels of corticosteroids following the induction of the 
immune response. These studies demonstrated that activated lymphocytes produce a 
soluble heat labile factor which can mediate this immune-induced increase in 
glucocorticoids in vivo. This factor, termed glucocorticoid-increasing factor (GIF), 
appears to act at the level of the pituitary to release AC1H. 
During an immune response, researchers have determined that there are specific 
alterations in the activity of the central nervous system which coincide with alterations in 
the levels of glucocorticoids. A selective decrease in hypothalamic norepinephrine has 
been demonstrated during the peak time of an immune response (Besedovsky et al. , 
1983; Carlson et al. , 1987). Dunn (1988) extended this observation by demonstrating 
that peripheral administration of IL-1 resulted in an increase of a norepinephrine 
metabolite (MHPG) in the hypothalamus and determined that this increase in 
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noradrenergic activity occurred during the time when corticosterone levels were rising in 
the plasma. 
Stimulating the HPA axis can result in glucocorticoid- and catecholamine­
induced alterations in lymphocyte migration (reviewed by Ottaway and Husband, 1992). 
Glucocorticoids alter the functional ability of immunocytes through direct destruction of 
lymphoid cells and suppression of immune activation and cellular metabolism (Claman, 
1972). In addition, corticosteroids have been reported to specifically suppress the 
function of immunocompetent cells including macrophages (Snydar and Unanue, 1982), 
B lymphocytes (Del Rey et al. , 1984) and NK cells (Hatton et al. , 1982). Interestingly, 
different species demonstrate variable sensitivities to the effects of glucocorticoids with 
rodents classified as sensitive and humans classified as resistant (Claman, 1972). 
Moreover, there is a differential sensitivity of lymphoid cells to the effects of 
corticosterone. The immune cell which has been reported to be the most sensitive to 
corticosteroids is the bone marrow derived B cell precursor (Cohen 1971). This 
observation has been substantiated by McMillian and colleagues (1988) who reported 
that resting B cells were more sensitive to corticosteroid-induced suppression than 
activated B cells. T lymphocytes also appear to display a differential sensitivity for 
glucocorticoids. In mice, immature T lymphocytes residing in the cortex of the thymus 
were sensitive to corticosterone whereas the immunocompetent T lymphocytes located in 
the medulla were resistant to the effects of this hormone (Cohen and Claman, 1971). In 
apparent contrast, human thymocytes have been reported to be equally sensitive to the 
effects of dexamethasone (Nieto et al, 1992). 
Recent research has provided insight into the molecular nature of steroid-induced 
modulation of the antibody response. The expression of class II MHC molecules on the 
surface of B lymphocytes is suppressed in a protein synthesis-dependent fashion by 
corticosteroids (McMillian et al., 1988) .  Furthermore, glucocorticoids have been 
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demonstrated to differentially regulate the secretion of the Tu lymphocyte cytokines IL-2 
and IL-4, whereby IL-2 secretion is reduced and IL-4 secretion is enhanced (Daynes and 
Araneo, 1989). The glucocorticoid-induced alteration in IL-2 activity has recently been 
determined to involve a downregulation of IL-2 mediated signal transduction in activated 
T lymphocytes (Vacca et al, 1992; Paliogianni et al., 1993). This glucocorticoid-induced 
suppression of interleukin secretion at the level of the gene has previously been 
demonstrated for IL-6 (Ray et al., 1990). 
The biological actions of glucocorticoids occur through a receptor mediated 
event. Once corticosteroids bind to their cell surface receptor, the hormone-receptor 
complex is translocated to the nucleus of the cell where it binds to a specific domain on 
the DNA and subsequently regulates the transcription of various proteins (Chan and 
O'Malley, 1978). The lymphoid organs have been demonstrated to contain different 
amounts of adrenal steroid receptors. The type II steroid receptor is classified as the 
glucocorticoid receptor and the type I steroid receptor is classified as the 
mineralocorticoid receptor. The thymus contains only type II, whereas the spleen 
contains both the type I and type II steroid receptors (Miller et al., 1990, Spencer et al., 
1991). Although the type I steroid receptor is classified as the mineralocorticoid 
receptor, it binds corticosterone with greater affinity than does the type II steroid 
receptor (Reul and De Kloet, 1985). The type I steroid receptor located in the 
hypothalamus has been reported to regulate circadian rhythm and the negative feedback 
inhibition of glucocorticoid secretion (Dallman et al., 1987). The type II steroid receptor 
has recently been demonstrated to mediate glucocorticoid-induced immune suppression 
in the spleen (Miller et al., 1991). 
Given the fact that glucocorticoids produce their effects through a receptor 
mediated event, the use of a receptor antagonist can effectively block these actions. In 
1980, Roussel-Uclaf developed RU 38486 (RU 486), a drug which can function as a 
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progesterone and glucocorticoid antagonist. RU 486 was demonstrated to block 
corticosteroid effects at the level of the receptor without producing any agonist effects 
(Philibert 1984). However, a study conducted by Van Voorhis and colleagues (1989) 
demonstrated that RU 486 may exhibit agonist activity in vitro. This apparent action of 
RU 486 in vitro has not been demonstrated in vivo. In a clinical study conducted by 
Laue and coworkers (1990), chronic administration of RU 486 to humans did not 
produce alterations in the immune parameters that were measured. 
The Sympathetic Nervous System 
Evidence has been provided by numerous investigators that the primary immune 
organs are innervated by the SNS. Adrenergic fibers have been demonstrated in the bone 
marrow (Kuntz and Richins, 1945; Calvo and Fortez-Vila, 1967). Research conducted 
by Byron (1972) suggested a functional role for this innervation in the bone marrow 
whereby �-adrenergic receptor stimulation increased cell cycling in bone marrow stem 
cells. Innervation of the thymus by adrenergic nerve fibers has been demonstrated by 
numerous investigators (Bulloch and Moore, 1981, Bulloch and Pomerantz, 1984; Felten 
et al., 1987; Kendall and Al-Shawaf, 1991). In addition, this immune organ secretes 
peptides know as thymosins which have been reported to have immunomodulatory 
activity (Goldstein et al., 1981; Hall and Goldstein, 1987). 
The secondary lymphoid organs including the lymph nodes (Giron et al. , 1980), 
GALT (gastrointestinal-associated lymphoid tissue) (Felten et al. , 1981) and spleen 
(Galindo and Imaeda, 1962; Williams et al. , 1980; Felten et al. , 1987; Bellinger et al. , 
1990) also have a rich supply of adrenergic nerve fibers. Many investigators have 
focused on the SNS innervation into the spleen given the fact that this immune organ is 
the source for immunocompetent cells for various in vitro and in vivo studies assessing 
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the function of the immune system. The adrenergic innervation into the spleen follows a 
distinct pattern which travels along the vasculature of the spleen and terminates in the T­
lymphocyte area, known as the periarteriolar lymphoid sheath (PALS) region (Felten et 
al., 1 985). This innervation into the PALS region produces a very intimate association 
between the adrenergic nerve terminals and the T-lymphocytes. Recent evidence has 
also demonstrated the existence of neuropeptide-Y innervation in the spleen (Romano et 
al., 1991)  and the absence of cholinergic innervation (Bellinger et al., 1 993). Although 
norepinephrine is the primary neurotransmitter in adrenergic neurons, these neurons also 
contain enkephalin, neurotensin, neuropeptide Y and cholecystokinin (Hokfelt et al., 
1984). 
The J3-adrenergic receptor has proven to be an important element in the efferent 
signaling process between the SNS and the immune system. J3-adrenergic stimulation 
was found to increase thymocyte maturation (Singh and Owen, 1976). The existence of 
J3-adrenergic receptors on murine lymphocytes (Singh et al. , 1979) as well as human 
lymphocytes (Meurs et al. , 1 982) has been known for over a decade. Singh and 
coworkers ( 1979) demonstrated that the density of J3-adrenergic receptors on murine 
lymphocytes is greater on fetal cells compared to adult cells, and that stimulation of this 
receptor on lymphocytes resulted in an increase in the second messenger, 3', 5'-cyclic 
adenosine monophosphate ( cAMP). This receptor has also been reported to have a 
greater density on B-lymphocytes compared to T-lymphocytes (Fuchs et al. , 1 988a). 
Studies conducted by Loveland and colleagues ( 1981)  determined that the J3-adrenergic 
receptor on murine lymphocytes was of the J32-adrenergic receptor subtype. In addition 
to the J3-adrenergic receptor, a number of other neuroendocrine receptors have been 
identified on immunocytes, including receptors for ACTH, VIP, substance P, prolactin, 
growth hormones, steroids, catecholamines and acetylcholine (Khansari et al. , 1 990). 
The literature investigating the modulation of the immune response by the SNS 
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has been confounded by reports suggesting that the SNS is a negative modulator 
(Besedovsky et al., 1979; Del Rey et al. , 198 1 ;  Del Rey et al. , 1982) as well as a positive 
modulator (Fuchs et al. , 1988a, 1 988b). The evidence which supports a negative 
modulatory role for the SNS has demonstrated that during an immune response in the 
spleen there is a decrease in the total level of splenic norepinephrine (Besedovsky et al. , 
1979; Mackenzie et al. , 1989). However, research conducted by Fuchs and colleagues 
has suggested that rather than a decrease in the concentration of splenic norepinephrine, 
there was actually an increase in norepinephrine turnover in the spleen following in vivo 
sensitization (Fuchs et al. ,  1988b). Furthermore, since receptor desensitization is a well 
established phenomenon (Hausdorff et al., 1990), this increase in norepinephrine 
turnover is substantiated by the evidence that there is a decrease in the density of �­
adrenergic receptors on lymphocytes (Fuchs et al. , 1988a). These studies suggest that 
the SNS is activated during an immune response in the spleen. Studies conducted by 
Jones and coworkers ( 1986) suggested that IL- 1 mediated a sepsis-induced increase in 
norepinephrine turnover in the spleen. This potential role of IL- 1 has been supported by 
studies which confirmed that IL- 1 does increase norepinephrine turnover in the spleen 
(Akiyoshi et al. , 1990; Saito et al. , 199 1). These studies provide further evidence which 
indicates that this cytokine may be a key component mediating immune-induced SNS 
activation. 
Numerous studies provided evidence for an immunoregulatory role for 
norepinephrine (reviewed by Sanders and Munson, 1985b). Norepinephrine has been 
demonstrated in vitro to have a positive modulatory effect on the primary antibody 
response (Sanders and Munson, 1984a, 1984b). Subsequent studies performed by 
Sanders and Munson ( 1985a) determined that while the norepinephrine-induced 
enhancement of the antibody response was mediated by an a 1-adrenergic mechanism, 
the activation of an a2-adrenergic mechanism produced a suppression of the antibody 
response. The signal transduction pathway mediating �-adrenergic receptor activation 
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leads to increased production of cAMP. Although Bourne and colleagues (1974) had 
classified cAMP as an inhibitor of leukocyte function, these studies indicate that 
increasing the levels of cAMP can enhance the in vitro AFC response. The 
immunoenhancing effect of norepinephrine may also be related to the work of Coffey 
and colleagues (1975) who demonstrated that norepinephrine can inhibit a lymphocyte 
plasma membrane ATP'ase through a �-adrenergic receptor mechanism. This effect 
mediated by norepinephrine provides a possible explanation for the studies conducted by 
Li and coworkers (1990) which indicated that �-adrenergic stimulation enhanced the 
humoral immune response by a cAMP-independent mechanism. 
Kinetic studies have revealed that the time at which the increase in the level of 
cAMP occurs during the immune response is critical to the outcome on the antibody 
response. Enhancement of the in vitro AFC response requires activation of adrenergic 
receptors within the first six hours following the initiation of the antibody response 
(Sanders and Munson 1984 ). This result is in agreement with Plescia and colleagues 
(1975) who demonstrated that during an antibody response, cAMP levels rise within two 
minutes then fall within 20 minutes. In light of the evidence that dividing cells have a 
much lower level of cAMP than non-dividing cells (Watson, 1975) this modulation of 
cAMP levels during the production of antibody would be expected. Kately and 
Friedman ( 197 5) demonstrated that increasing the level of cAMP at the time of 
sensitization would result in enhancement whereas an increase in cAMP prior to 
sensitization would produce suppression. The literature has reported that the level of 
cAMP can regulate the differentiation of T-lymphocytes (Bach et al., 1975; Scheid et al., 
1975). However, studies conducted by Gilbert and Hoffmann (1985) demonstrate that 
while increased levels of cAMP are able to enhance the function of B-lymphocytes, 
elevation of cAMP can result in the suppression of Twlymphocyte function. Additional 
evidence supporting a role for adrenergic-mediated suppression of T-cell function was 
provided by a study conducted by Cunnick and coworkers (1990) which suggested that a 
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P-adrenergic mechanism was mediating stress-induced suppression of splenic T­
lymphocyte mitogenesis. 
Until recently, the mechanism mediating P2-adrenergic receptor-induced 
enhancement of in vitro antibody production was unknown. A study conducted by 
Sanders and Powell-Oliver ( 1992) determined that the P2-adrenergic receptor induced 
increase in antibody production was the result of an increase in the number of responding 
B-lymphocytes rather than as a result of increased burst size. In contrast, other 
investigations have reported that adrenergic stimulation suppresses the function of 
specific cell targets. In vitro studies which assessed macrophage function demonstrated 
that norepinephrine suppressed the production of TNF (Hu et al. , 199 1 ). A recent report 
by Helig and coworkers ( 1993) has suggested that adrenergic stimulation impairs 
humoral immune function at the level of antigen processing and presentation. 
Reports in the literature suggest that in certain animal models, decreases in P­
adrenergic receptor density (Carr, et al. , 1993) and splenic noradrenergic innervation 
(Breneman et al. , 1 993) may be linked to immune dysfunction. Although numerous 
studies have explored the modulatory role of the SNS on the humoral immune response, 
the phenomenon of in vivo regulation of the antibody response by norepinephrine is 
poorly understood. 
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Evidence for Neuroimmunomodulation 
Sympathectomy-Induced Alterations in Humoral Immunity 
In  an  attempt to invest igate the in vivo regulation of the immune response by the 
SNS, researchers have employed experimental models which assessed immune fu nction 
following the removal of the SNS. The abil ity  of the adre ne rgic neu rotox in, 6-
hydroxydopamine (6-OHDA; 2,4,5-trihydroxyphenylethylamine), to produce a chemical 
sympathectomy was fi rst demonstrated by Porter and colleagues in 1963. The l ite rature 
has since revealed that 6-OHDA has been  the most common method empl oyed  by 
scientists to remove the SNS. Stone and colleagues (1963 ) determined that the ability of 
6-OHDA to deplete adrenergic neurons was superior to that of other pharmacological 
age nts  such as  rese rpine or guanethidine. The specifi city of 6-OHDA for depleting 
catechol amine s  is attributed to the fact that it is sele ct ively  taken up into adrene rgic 
neurons by the catecholamine uptake pu mp (Thoenen and Tranzer, 1968 ) and appears to 
replace norepinephrine w ithin the ne rve te rminal (Porter et al., 1965 ) .  6-OHDA 
competitively inhibits the uptake of norepinephrine into adrenergic neu rons and has been 
demonstrated to have a Ki of approximately 22 µM (Iversen 1970). Depicted in Figure 4 
are the actions of 6-OHDA on the adrenergic nerve terminal. 
While comparing the effects of 6-OHDA and a congener, 5- hydroxydopamine (5-
OHDA; 3,4 ,5-t rihydrox yphenylethyla mine ), on adrene rgic neu rons, Tranze r and 
Thoenen (1968 ) clearly demonstrated that only  the neu rons treated w ith 6-OHDA were 
de stroyed  even  thou gh 5-OHDA was al so taken  up  into the ne rve te rminal s. The 
destruction of the adrenergic nerve terminal s by 6-OHDA appears to be mediated by the 
generation of reactive metabol ite s (Thoenen and Tranze r, 1973 ; Jonsson and Sachs, 
1975 ). A study condu cted by Graham and colleague s (1978 ) su ggests that 6-OHDA-
Mitochondrial 
MAO 
� 
 
6-0HDA -◄--►- PQ 
6-0 HDA •◄i-------4►• PQ 
Storage 
Vesicles 
DISPLACED 
Norepinephrine 
Figure 4. Actions of 6-0HDA on the adrenergic nerve terminal. 
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induced c ytotoxicity is medi ated  primari ly by the hydrogen peroxide, hydroxy l  radic al 
and superoxide radic als formed upon 6-0HDA oxidation rathe r t han the p ara-quinone 
(PQ) metabolite. However, the disparity i n  neu rotoxic p otentials between 6-0HDA and 
5-0HDA may be attri buted to the fact that 6-0HDA is oxidized  to a PQ metabolite whi le 
5-0HDA is not ( Figu re  5). This wou ld be consistent with the experiments reported by 
Jonsson and Sac hs (1975) which demonstrated that the PQ metabolite was more toxic 
than the ortho-quinone (OQ) metabolite. 
The lite ratu re desc ri bi ng the humoral immu ne effects fo llowi ng pe riphe ral 
sympathectomy with 6-0HDA has reported i ncreases ( Besedovsky et al., 1979; Wi lliams 
et al. , 1981 ; Mi les et al. ,  1981), dec re ases (Kas ahara et al., 1977 ; Hall et al. ,  1 982; 
Livnat et al. , 1985; Fuchs et al. , 1988 b), or no change (Mi les et al., 1981) i n  the in vivo 
generated antibody fo rming cell ( AFC) response. These inconsistencies in  the literature 
may be attri buted to a number of factors which are discussed below. 
The mouse strain  that is use d for expe ri me nts emp loyi ng 6-0HDA is an 
important conside ration when assessi ng experimental resu lts. Li vnat and colle agues 
(1985) have reported that di ffe rent strai ns of mice will exhi bit varying amou nts of 
immune suppression fo llowing sympathectomy with 6-0HDA. Therefo re, it is possi ble 
that t he variations in  immune responsiveness fo llowing 6-0HDA treatment are re lated to 
strain  differe nces, as the experiments reporte d in  the 6-0HDA lite rature sited p re viously 
were conducted in such mouse strains as B6C3 F l, C3 H, C57 Bl/6, and NJ. 
Stu dies have demonstrated that the re are age- re lated effects on the immune 
response depending on whether  the sympathectomy occurs in  neonatal versus adu lt mice. 
This may be re lated to the fact that this chemic al c an produce central effects in  neonates 
w hich do not have a fully de ve loped blood- brain barrie r. I n  addition, 6-0HDA treatment 
i n  neonatal mice produces a permanent sympathectomy where as in  adu lt animals, there is 
regenerati on of adrene rgic ne rve terminals which can begi n  as early as one to fi ve days 
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Figure 5. Toxic species generated by the oxidation of 6-0HDA. 
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following the administration of 6-OHDA (Jonsson and Sachs, 1970; Lorton, et al. , 
1990). 
The dose and route of administration are important factors given the evidence 
that a sufficiently high dose of 6-OHDA is required in vivo in order for there to be 
adequate destruction of the nerve terminal (Thoenen and Tranzer, 1968). Furthermore, 
Thoenen and Tranzer ( 1968) determined that 6-OHDA can exhibit false transmitter 
properties when administered in low doses. In addition, although the norepinephrine 
content of adrenergic neurons may decrease, the uptake of norepinephrine returns to 
normal within a few hours following a low dose of 6-OHDA (Jonsson and Sachs, 1970). 
Due to the fact that 6-OHDA does not appear to cross the adult blood brain barrier 
(Cuello et al. , 197 4 ), the effects on immune function observed following peripheral 
administration of 6-OHDA may be different from what is demonstrated following central 
administration. 
The in vivo administration of 6-OHDA causes a transient sympathomimetic effect 
(Stone et al., 1963). The uptake of 6-OHDA by the catecholamine pump displaces 
norepinephrine from storage vesicles from within the adrenergic nerve terminal. This 
displacement of norepinephrine could potentially cause the downregulation of J3-
adrenergic receptors on splenic lymphocytes. This event may uncouple the signal 
transduction pathway needed to alter the levels of cAMP in immunocompetent cells. 
Since it has been demonstrated that modulation of cAMP levels in lymphocytes at 
specific times can alter the antibody response, it would appear that the time of chemical 
administration relative to the time of sensitization with antigen would be a key factor. 
The type of antigen used for sensitization (T-dependent versus T-independent) 
also appears to be a factor in 6-OHDA-induced immune modulation (Miles et al., 198 1 ). 
This would be expected given the evidence that there may be a differential effect of 
adrenergic stimulation on immunocompetent cells. 
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The modulation of humoral immune function following central administration of 
6-0HDA has provided important evidence supporting neuroimmunomodulation. A 
study conducted by Cross and coworkers (1986) demonstrated that depletion of 
catecholamines in the cistema magna produced a suppression of both the IgM and IgG 
AFC response. In a subsequent study (Cross et al., 1987), this group also determined 
that central administration of 6-0HDA results in an induction of an antigen nonspecific 
population of suppressor T lymphocytes. Furthermore, hypophysectomy effectively 
prevented this induction, thereby implicating a role for the pituitary in this immune 
dysfunction following the depletion of catecholamines in the central nervous system. 
Enhancement of immune function has also been reported. Braun and coworkers (1988), 
in a model which used unilateral superior cervical ganglion sympathectomy, 
demonstrated an increase in the lymph node antibody response. 
Sympathectomy-Induced Alterations in Cellular Immunity 
Chemical sympathectomy has been demonstrated to produce a suppression in 
cell-mediated immune function. Peripheral administration of 6-0HDA was found to 
decrease delayed type hypersensitivity (Madden, et al., 1989). In addition, decreases in 
both T-lymphocyte and B-lymphocyte proliferation have been demonstrated in adult rats 
which were sympathectomized in the neonatal period (Ackerman et al., 1991). In 
contrast, Lyte and coworkers (1991) have reported that 6-0HDA treatment in certain 
strains of mice caused an enhancement of T-cell mitogenesis. This increase in T­
lymphocyte function following sympathectomy is supported by studies conducted by 
Braun and coworkers (1988) who demonstrated an increase in the delayed type 
hypersensitivity reaction in a model employing a unilateral superior cervical ganglion 
sympathectomy. 
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Lesions to specific areas in the brain have been demonstrated to have significant 
effects on the immune response. Jankovic and Isakovic (1973) demonstrated 
suppression of delayed hypersensitivity and antibody production following lesions to the 
hypothalamus and reticular formation. Studies by other investigators have found that 
lesions to hypothalamic structures caused a suppression in the colony formation ability 
of hematopoetic stem cells (Korneva and Lesnikov, 1988) and a suppression in T­
lymphocyte mitogenesis (Cross et al.. , 1980). These studies provide evidence that the 
hypothalamus is an important component in the central nervous system regulation of 
immunity and suggest that lesions in the hypothalamic area of the brain could in effect 
disrupt the adrenergic activity in the central nervous system necessary to maintain 
normal immune function. 
Sympathectomy induced by 6-OHDA has been demonstrated to enhance TNF 
secretion in macrophages (Chelmicka-Schorr et al. , 1992a). This increase in 
macrophage function following depletion of catecholamines has been demonstrated to 
have functional significance in an animal model of autoimmune disease whereby there is 
an increase in the severity of the disease following sympathectomy (Chelmicka-Schorr et 
al., 1992b). These studies suggest that the SNS may be a negative modulator of 
macrophage function and support the evidence provided by Teh and Paetkau (1976) 
which demonstrated that elevation of cAMP resulted in the suppression of macrophage 
function. Although these studies found that macrophage function was enhanced, other 
investigators have reported that the functional capacity of NK cells in the spleen was 
suppressed (Won and Lin, 1989) or unaffected (Brenner et al. , 1992) following 
peripheral depletion of catecholamines. 
Evidence for a positive modulation of host defense by the SNS has been provided 
by Vinnitsky (1988) who determined that electrical stimulation of the hypothalamus 
resulted in pronounced antitumor effects. This research has been supported by Brenner 
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and colleagues (1992) who demonstrated that by depleting catecholamines with 6-
OHDA prior to tumor challenge there was in increase in tumor formation. 
Experimental and Clinical Evidence for Neuroimmunomodulation 
Modulation of immunity through behavioral conditioning (reviewed by Ader, 
1985) has been an area of intense interest as this provides researchers with a model to 
study neuroimmunologic interactions. This behavioral conditioning involves first 
pairing a novel taste (conditioned stimulus) with an immunomodulating agent 
(unconditioned stimulus). Following a subsequent exposure to this conditioned stimulus, 
the immune system responds as if the immunomodulating agent had been administered. 
Studies have revealed that suppression of the antibody response (Ader and Cohen, 1975), 
delayed type hypersensitivity (Kelley et al, 1988), and decreased severity of autoimmune 
diseases (Klosterhalfen and Klosterhalfen, 1992), and graft rejection (Schedlowski et al., 
1992) may occur following behavioral conditioning. Greenberg and colleagues (1992) 
have suggested that IL-1 is an important mediator in conditioned immunosuppression. 
Despite evidence provided by Roudebush and Bryant (1991) that conditioned 
suppression of delayed type hypersensitivity was not mediated by an increase in 
corticosterone, Greenberg and colleagues (1992) suggest that HPA and SNS stimulation 
mediated by IL-1 is a key regulatory pathway in conditioned immunosuppression. 
In addition to immunosuppression, behavioral conditioning has also been 
reported to enhance immune function. Studies have demonstrated an increase in NK cell 
activity (Solvason et al, 1988; Ghanta et al., 1988) and allergic reactions (Gauci et al., 
1992) following behavioral conditioning. In addition, a recent report has provided 
evidence that behavior without conditioning may also lead to an enhancement of the 
immune response whereby a greater antibody response was displayed by aggressive, 
rather than submissive mice (Devoino et al., 1993). 
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Vari ous physiologic con ditions w hic h alte r normal homeostasis, includin g 
disease processes, depression, and stress, have been dem onstrated to alte r immune 
function. Clinical evidence, which was provided as far back as 150 A.D. with the Greek 
physician Galan, suggests a link between depression and immune dysfunction (Schleife r 
et al., 1 984). Humans subjected to stress have dem onstrated dec reases in NK cell 
activity, y-interferon production, T-lym phocyte number and mitogenesis, and an inc rease 
anti-vi ral tite rs (reviewed by Bonneau et al., 1990; Kemeny et al., 1992). 
One of the m ost definitive methods for  determining whethe r  or not the central 
nervous system inte racts with the immune system is to  perform surgical or c hemical 
ablation on specific areas in the brain and assess the function of the immune response. 
Stu dies conducted by Biziere and colleagues (1985) have dem onstrated that lesions to 
specific area of the cerebral cortex lead to a dec rease in the num her and functionality of 
splenic T-lym phocytes. This apparent association between dys function in certain areas 
of the brain an d altered  immunity has been supported by the observation that the re is a 
relationship  between le ft handedness, learning disorders and a dec rease in the functional 
capacity of the immune system (Behan and Geschwind, 1985 ). 
The ex pe rimental an d clinical stu dies desc ri bed in the lite ratu re provide 
int ri guin g insi ght into the potential inte racti ons whic h ma y exist between t he 
neuroen docrine and immune systems. A key factor fo r  scientists conducting research in 
the area of neuroimmun omodulation will be to un de rstand the nature of the regu lation 
between these two systems. 
MATERIALS AND METHODS 
Animals 
Assays were conducted with virus free female C57BU6 X C3H F l  (B6C3Fl)  
mice from Taconic Farms (Germantown NY) or the National Cancer Institute (NCI; 
Frederick, MD). A limited number of studies were conducted with female C3H/He mice 
from the NCI. In all experiments, mice were between 6 and 8 weeks of age. A 
quarantine period of one week was implemented before the animals were used. Animals 
were housed four to a cage and provided with a "virus-free" environment which 
consisted of cages capped with filter hoods and sawdust bedding which was changed 
twice weekly. Mice were fed Purina Lab Chow and tap water ad libitum. The animals 
were maintained on a 12-hour light-dark cycle, in a temperature range between 21 and 
24°C, and humidity between 40 and 60%. To ascertain the health of the colony, the 
"sentinel mice" which occupy each animal room were sacrificed and studied at regular 
intervals to determine the presence of murine hepatitis virus or Sendai virus. 
Reagents 
Complete culture media for in vitro antibody cultures was prepared with RPMI 
1640 (Sigma) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin (all from GIBCO, Grand Island, NY), 2.25 mg/ml sodium bicarbonate, 
(Sigma), 25 mM Hepes buffer (Sigma), 50 µM 2-mercaptoethanol (2-ME; Sigma) and 
10% fetal bovine sera (Hyclone, Logan UT). Culture media for DNA fragmentation 
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assays consisted of the complete media described above without the addition of 2-ME. 
Hanks Balanced Salt Solution (HBSS) was also obtained from Sigma and supplemented 
with Hepes. 
Chemicals and Pharmacological Agents 
6-hydroxydopamine hydrobromide (6-OHDA), 5-hydroxydopamine hydro­
chloride (5-OHDA), desipramine hydrochloride (DMI; desmethylimipramine), 
norepinephrine hydrochloride and DL-propranolol hydrochloride were obtained from 
Sigma Chemical Co. (St. Louis, MO). Phentolamine hydrochloride and chlorisondamine 
were kindly provided by CIBA-GEIGY (Summit, NJ). These compounds listed above 
were prepared in saline immediately prior to utilization. RU-38486 (RU-486), was a gift 
from Roussel-Uclaf (Paris, France) and was prepared in Ringer's solution containing 
0.2% methylcellulose and 0.2% Tween 80 and vortexed continually for at least two 
hours prior to utilization. Corticosterone (Sigma) was either prepared in the same 
vehicle as RU-486 for in vivo studies, or was dissolved in 1.0% dimethyl sulfoxide 
(DMSO; Sigma) for in vitro studies. 
Implantation of Mini Osmotic Pumps 
Mini osmotic pumps (Model 1007D) were purchased from Alza Corporation 
(Palo Alto, CA). Using sterile technique, pumps were loaded with vehicle or 
chlorisondamine according to manufacturers directions and incubated at 37°C for at least 
4 hours in sterile saline to prime the pumps prior to implantation. The weight of the 
pumps was assessed prior to and following loading in order to determine the net weight 
of the solution loaded and to insure accurate filling. 
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Mice were sedated with an intraperitoneal (i.p.) injection of 55 mg/kg Nembutal 
(pentobarbital) in a volume of 0.2 ml (due to the length of the recovery time for the 
chlorisondamine-implanted mice, this dose of Nembutal was decreased to 41 mg/kg). 
The dorsal region of the mice was shaved, then swabbed with iodine solution. 
Anesthesia was maintained throughout the surgical procedure with inhaled Metofane 
(methoxyflurane; Pitman-Moore, Mundelein, IL). A 1 cm transverse incision was made 
on the back and a subcutaneous pocket created with scissors. The pump was inserted 
with the modulator facing away from the incision with a pair of forceps. A surgical 
staple was used to seal the wound and the surrounding area was swabbed with iodine 
solution. Mice recovered in cages warmed with heating pads until their righting reflex 
was restored. 
Preparation of Sheep Erythrocytes 
The sheep erythrocytes (sRBC) were obtained from Colorado Serum (Denver, 
CO). Prior to utilization in the in vitro assays or for in vivo antigen sensitization, cells 
were washed once with Alsever's (Sigma) and twice with HBSS ( 800 x g at 4°C for 10 
minutes). 
The Primary Antibody Forming Cell (AFC) Response 
The primary splenic antibody forming cell (AFC) response to the T-dependent 
antigen, sRBC, was assessed using a modified cell culture system originally described 
by Mishell and Dutton (1967). Spleens were asceptically removed from naive or treated 
mice and placed into a sterile tube containing 3 ml HBSS. A single cell suspension was 
prepared by gently mashing the spleen between the frosted ends of two glass slides 
under sterile conditions. Splenocytes were centrifuged at 300 x g at 4°C for 10 minutes, 
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resuspended in 3 ml complete RPMI media per spleen, and cell counts determined on a 
model ZBI Coulter counter (Coulter Electronics, Hialeah, FL). Equal numbers (5xl 06) 
of splenocytes and washed sRBC were pipetted into a 48-well culture plate (Costar, 
Cambridge, MA) to a final volume of 500 µl. Plates were placed into a sealed steel box 
containing 7% 02, 10% C(h and 83% N2 at 6 psi pressure and incubated at 37 °C on a 
rocking platform. On day 5 of culture, the number of lgM AFC were enumerated by the 
hemolytic plaque assay (described below). A diagram depicting this assessment of the 
primary antibody response can be viewed in Figure 6. Detailed below are the in vitro-in 
vitro, in vivo-in vitro, and in vivo-in vivo study designs, as described by Holsapple (in 
press), utilized to evaluate the primary AFC response. 
In Vitro-In Vitro Studies 
The primary AFC response, as described above, was assessed in vitro with 
cultures containing increasing concentrations of 6-OHDA or 5-OHDA (0.01 - 1 mM) or 
chlorisondamine (0.1 nM - 0.1 mM). Compounds were diluted in complete RPMI media 
and added in a 50 µl volume to the culture wells following the addition of splenocytes 
and sRBC. On day five of culture, the number of lgM AFC was enumerated as 
described in the Hemolytic Plaque Assay. Initially, the splenocyte viability on day five 
of culture was determined by a modification of the Pronase method described by 
Holsapple et al. (1984). For a more accurate assessment, subsequent studies utilized 
propidium iodide exclusion (described in Immunofluorescent Staining and Flow 
Cytometric Analysis) to determine splenocyte viability. 
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Figure 6. The in vitro generated primary antibody response. 
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In Vivo-In Vitro Studies 
The paradigm for the in vivo-in vitro studies is depicted in Figure 7. Mice 
received an i.p. injection of vehicle (saline), 200 mg/kg 6-OHDA or 200 mg/kg 5-
OHDA (diluted in saline) in a 0.2 ml volume, on five days and two days prior to 
sacrifice. At the time of sacrifice, body weights were determined and spleens were 
asceptically removed and weighed. Splenocyte suspensions were prepared from 
individual spleens, placed into culture, then sensitized with sRBC. The number of IgM 
AFC was quantitated on day five of culture as described under the Hemolytic Plaque 
Assay. Splenocyte viability on day five of culture (and in studies assessing splenocyte 
viability on the day of sacrifice) was determined by propidium iodide exclusion as 
described in Immunofluorescent Staining and Flow Cytometric Analysis. Early studies 
assessed viability by a modification of the Pronase method described by Holsapple et al. 
(1984). 
In Vivo-In Vivo Studies 
The in vivo-in vivo AFC response was evaluated following either 6-OHDA, 5-
OHDA, or chlorisondamine treatments. Depicted in Figure 8 is the paradigm for the 6-
OHDA and 5-OHDA studies. Mice received an i.p. injection of vehicle, 200 mg/kg 6-
OHDA or 200 mg/kg 5-OHDA three days before immunization. A second dose of 200 
mg/kg chemical was administered i.p. 30 minutes prior to the mice receiving an 
intravenous injection of lx  108 sRBC (0.2 ml volume). In the chlorisondamine studies, 
mice were implanted with pumps containing either vehicle (saline) or chlorisondamine 
(12 or 20 mg/kg) on the day prior to sensitization. In all studies, mice were sacrificed 
four days post immunization and body and spleen weights determined. The Hemolytic 
� ln�peritoneal injection 
"
of VH or Chemical 
Day -5 
� Intraperitoneal injection 
"
of VH or Chemical 
Day -2 
Day 0 
Weight and Cellularity 
FACScan Analysis 
Mishell Dutton Assay 
Weight and Cellularity 
F ACScan Analysis 
Figure 7. Model for in vivo-in vitro studies with 6-OHDA 
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Plaque �ay (described below) was performed on each spleen to enumerate the number 
of lgM AFC. 
1ime of Sensitization Studies 
Studies were designed to assess the effect of varying the time of sensitization on 
the in vivo-in vivo AFC response following 6-OHDA and 5-OHDA treatment. Mice 
received an initial i.p. dose of vehicle or chemical (200 mg/kg) three days prior to the 
day of sensitization. On the day of sensitization, mice received an intravenous injection 
of l x l 08 sRBC either two hours prior to, thirty minutes following, or two hours 
following administration of a second dose of vehicle or chemical. Additional studies 
determined the effect of sensitizing mice 24 hours prior to or 48 hours following second 
dose of vehicle or chemical. In all studies, the Hemolytic Plaque Assay (described 
below) was performed four days following sensitization and the number of IgM AFC 
determined. 
The Hemolytic Plaque Assay 
The number of lgM antibody forming cells (AFC) was determined by a 
modification of the Jeme hemolytic plaque assay (Bullock and Moller, 1972) as 
described by Holsapple et al. (1984). For studies which assessed the in vitro generated 
AFC response, an aliquot of 50 µl splenocytes was mixed with 25 µl sRBC, 25 µl guinea 
pig complement (1:3 dilution of reconstituted lyophilized powder, GIBCO) and 400 µl 
agar (0.7% Bacto-agar, Difeo with 0.1 % DEAE-Dextran, Pharmacia). A 200 µl aliquot 
of this mixture was pipetted onto a plastic petri dish and a glass coverslip overlayed. For 
studies evaluating the in vivo generated AFC response, an aliquot of 100 µl splenocytes 
( 1 :30 dilution of splenocyte suspension) was mixed with 25 µl sRBC, 25 µl guinea pig 
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complement and 350 µl agar. A 200 µl aliquot of this mixture was pipetted onto a 
plastic petri dish and a glass coverslip overlayed. Through the production of specific 
antibody and the action of complement, the sRBC surrounding the antibody-secreting B­
lymphocytes will be lysed to form a zone of hemolysis (plaque). The plaques, or 
specific AFC, were enumerated under a dissecting microscope or a plaque viewer 
(Bellco Glass, Inc., Vineland, NJ) at the end of a three hour incubation at 37°C. An 
example of an antibody-secreting B-lymphocyte is illustrated in Figure 9 (magnification: 
40x). Data are reported as the number of lgM AFC /106 splenocytes or the number of 
lgM AFC per spleen. 
ImmunoDuorescent Staining and Flow Cytometric Analysis 
Lymphocyte subpopulations in the spleen and thymus were evaluated using 
fluorescently conjugated monoclonal antibodies and flow cytometric analysis. Cell 
suspensions were prepared from spleens or thymuses obtained from mice which were 
dosed using either the in vitro-in vivo or in vivo-in vivo experimental paradigms 
described previously. Cells were stained with the following monoclonal antibodies 
(1:25 dilution, Becton Dickenson, San Jose, CA): fluorescein isothiocyanate (FITC)­
conjugated anti-Lyt-2 (clone 53-6.7; rat IgG2a) to detect CDS+ lymphocytes, 
phycoerythrin (PE)-conjugated anti-L3T4 (clone GK 1.5; rat lgG2b) to detect CD4+ 
lymphocytes, and a ATC-conjugated goat anti-mouse lg to detect B lymphocytes. 
The staining procedure was performed as described by Sikorski et al. (1991). 
Cell suspensions were prepared by gently mashing spleens and thymuses in HBSS 
between the frosted ends of microscope slides. Cells were centrifuged at 300 x g for 10 
minutes, resuspended in 3 ml HBSS (for spleens in the in vivo-in vivo studies, cells were 
resuspended in 3 ml complete RPM!) and cell counts determined using a ZBI Coulter 
Counter. An appropriate volume to yield a concentration of 1.5 x 1 ()6 cells was pipetted 
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Figure 9. The antibody-secreting B lymphocyte. 
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into a 96-well U-bottom plate (Costar). A 100 µl volume of staining buffer (PBS with 
0.1% BSA and 0.1% NaN3 solution) was added to each well and the plate centrifuged 
for 2 minutes at 300 x g. Following two washes, a 150 µl volume of the appropriate 
monoclonal antibody was added and cells incubated for 30 minutes at 4°C. Cells were 
then washed one time, a volume of 150 µl of 0.005 mg/ml propidium iodide (PI; Sigma) 
added to each well, and cells incubated for an additional five minutes a 4 °C. Staining 
cells with PI allowed for live gating analysis whereby dead cells, which stained positive 
for PI, were gated out Following PI incubation, cells were washed an additional two 
times, then resuspended with 150 µl staining buffer. 
Viability determinations using PI exclusion were performed on splenocytes and 
thymocytes obtained from in vitro studies. An aliquot of 100 µl cultured cells was 
washed two times with staining buffer and stained with 150 µl PI as described above. 
Splenocytes (1.5 x 106) obtained from in vivo-in vitro and in vivo-in vivo studies were 
stained with 150 µl PI to determine splenocytes viability on the day of sacrifice 
Stained cells were analyzed with a Becton-Dickinson FACScan™ (Fluorescent 
Activated Cell Sorter) flow cytometer which featured a low-power 15 mwatt argon-ion 
laser (488 nm) and three high performance photomultiplier tubes for green (FITC), 
orange (PE), and red (Pl) multicolor analysis. Data were analyzed using FACScan™ 
Research software which generated either a histogram or a four quadrant dot plot (log 
green fluorescence versus log orange fluorescence) for evaluation of specific cell 
subpopulations (Figure 10). For viability analysis, data are reported as % viability as 
determined by the number of cells which did not stain positive for PI. For specific cell 
surface marker analysis, data are reported as either the % of cells staining positive for a 
specific cell surface marker, or as the absolute number of cells as determined by 
multiplying the % positive by the total number of cells in the spleen or thymus. 
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Quantitation of Splenic Norepinephrine 
The dosing paradigm described for in vitro-in vivo studies was employed and the 
levels of splenic norepinephrine (NE) determined. Immediately following euthanasia by 
CO2 overexposure, spleens were removed from the mice, weighed, then placed into 1 ml 
ice cold PBS. Once spleens were mashed between the frosted ends of glass slides, 
splenic capsules were removed from the resulting cell suspension, blotted, then weighed. 
The splenic cell fraction and capsule were kept on ice throughout the extraction 
procedure. Following the transfer of the cell fraction into a glass grinding chamber 
(Thomas Scientific), the sample was acidified with 200 µl of 1.0 M perchloric acid 
(Aldrich Chemical Co., Milwaukee, WI), then ground with a tissue homogenizer (Belko 
Biotechnology) using a teflon pestle (Thomas Scientific). The homogenized sample was 
then transferred to a volumetric glass tube and brought up to 2 ml with PBS. The splenic 
capsule was acidified with 1 ml of 0.1 M perchloric acid, homogenized, and brought up 
to 2 ml with 0.1 M perchloric acid. The homogenized cell fractions and capsules were 
transferred to 2 ml microfuge tubes and centrifuged for 15 minutes at 7 500 x g .  Samples 
were filtered into glass vials using a Millipore filter (0.45 µm pore size) attached to a 1 
cc syringe, and stored at -70°C until the time of analysis. Due to the potential loss of NE 
upon storage, one study was set up with an internal standard. A 20 µl volume of 3,4-
dihydroxybenzylamine hydrobromide (DHBA; Sigma) was added to cell and capsule 
fractions prior to homogenization (final concentration: 100 pg/ml). 
NE levels were quantitated on a Waters (Milford, MA) HPLC (high performance 
liquid chromatography) system which included a Model 510 pump, a Model 460 
electrochemical detector (settings : +0.80 V potential, 2 nA range, 2 second time 
constant), and a Model U6K manual injector. A Model 740 data module was utilized to 
integrate the NE peak area. The level of NE in the samples was calculated from a 
standard curve generated from standards prepared from (-) arterenol (Sigma Chemical 
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Co., St. Louis, MO). The mobile phase consisted of 50 mM sodium acetate, 20 mM 
citrate, 1 mM dibutylamine (purchased from Aldrich), 3.75 mM sodium octyl sulfate, 
and 0. 1 35 mM sodium EDTA (purchased from Sigma) dissolved in a 5% HPLC-grade 
methanol (Fisher) and 95% water mixture. A Waters Resolve 5-mm C1s reverse phase 
column was used for the stationary phase. A catecholamine injection standard (Waters) 
was injected daily to verify the retention time for NE and determine that the system was 
functioning adequately (Figure 1 1). NE had a retention time of 4.9 minutes and a 
detection limit of 2.5 pg. Data are reported as the pg quantity of NE per mg of either 
splenic capsule or cell supernatant fraction. 
Blockade Studies 
Monoamine Uptake Blockade 
The ability of the adrenergic uptake blocker desmethylimipramine (DMI) to 
reverse the observed 6-OHDA-induced or 5-OHDA-induced suppression of the primary 
AFC response was assessed. For the in vitro-in vitro AFC response, cultures were 
established as described above with DMI (0. 1 and 1 .0 µM diluted in complete RPMI) 
added into culture wells prior to the addition of 6-OHDA or 5-OHDA (0.3 and 1 mM). 
The lgM AFC response was determined on day five of culture as described previously. 
In the DMI blockade studies investigating the in vivo-in vitro and in vivo-in vivo 
AFC responses in 6-OHDA and 5-OHDA treated mice, an i.p. dose of 25 mg/kg DMI 
(diluted in saline) was administered 30 minutes prior to each time mice received vehicle 
or a 200 mg/kg dose of 6-OHDA or 5-OHDA. The in vivo-in vitro and in vivo-in vivo 
AFC responses were determined as described previously. 
Studies were also conducted to assess the ability of DMI to block 6-OHDA­
induced alterations in splenic NE levels (described in Quantitation of Splenic 
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Norepinephrine), splenocyte and thymocyte subpopulations (under Immunofluorescent 
Staining and Flow Cytometric Analysis), and serum corticosterone (under Corticosterone 
Assay). In all experiments, DMI (25 mg/kg) was administered intraperitoneally 30 
minutes prior to each time mice received vehicle or chemical. 
Adrenergic Receptor Blockade 
Studies were conducted to investigate the mechanism of 5-OHDA-induced 
suppression of the in vivo-in vivo AFC response. Mice received either propranolol (0.3, 
3.0 or 30 mg/kg, i.p.) or phentolamine (0.3, 3.0 or 30 mg/kg, i.p.) 30 minutes prior to 
each time 5-OHDA (200 mg/kg) was administered. The in vivo-in v ivo AFC response 
was determined as described previously. 
Glucocorticoid Receptor Blockade 
Using the experimental paradigms described above, the potential role of 
glucocorticoids in the 6-OHDA-induced suppression of the in v ivo-in vitro and in-vivo in 
vivo AFC response and the chlorisondamine-induced suppression of the in vivo-in vivo 
AFC response was determined. Mice were pretreated with 200 mg/kg RU-486 (oral 
gavage) one hour prior to either an i.p. injection of 6-OHDA (200 mg/kg) or 
implantation with chlorisondamine (20 mg/kg/day). RU-486 was administered every 12 
hours thereafter for the duration of the studies and the AFC response determined as 
described in the Hemolytic Plaque Assay. 
The ability of RU-486 to block 6-OHDA-induced thymic apoptosis was also 
evaluated. Mice were pretreated with 200 mg/kg RU-486 (oral gavage) one hour prior to 
an i.p. injection of vehicle or 6-OHDA (200 mg/kg). RU-486 was administered either 
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every 12 hours or every nine hours thereafter and DNA fragmentation assessed at 24 
hours as described in DNA Fragmentation Following In Vivo Treatment 
Peripheral Blood Analysis 
The peripheral blood of mice dosed with the in vivo-in vivo paradigm ( described 
above) was colle.cted by retro-orbital bleed into heparinized micro-hematocrit capillary 
tubes (Fisher Scientific, Pittsburgh, PA) and transferred into 500 µl microtainer tubes 
with EDTA (Be.cton Dickinson). To determine hematocrit, a sample of blood was drawn 
up into a heparinized micro-hematocrit capillary tubes and sealed with vinyl plastic putty 
(Critoseal; Lancer). Capillary tubes were placed into a Model MB Micro-capillary 
centrifuge (International Equipment Company (IEC), Needham Hts., MA) and spun for 
3 minutes. Using the Micro-capillary reader (IEC), the % packed cells of the total 
volume was measured and reported as % hematocrit 
Peripheral blood hemoglobin was determined using a Hemoglobinometer 
(Coulter Ele.ctronics). Data are reported as G/dL. 
Cell counts were performed on a Coulter Counter to determine the number of 
peripheral blood erythrocytes and leukocytes. Data for the erythrocyte (RBC) number 
are reported as cells x 106 per mm3. Data for the leukocyte (WBC) number are reported 
as cells x 103 per mm3. 
Peripheral blood differentials were evaluated at various times following chemical 
administration in addition to the differentials performed on the blood obtained from the 
in vivo-in vivo paradigm. Blood smears were prepared on 3 x 1 inch glass slides, fixed 
with methanol, then stained with SureStain™ Wright-Giemsa (Fisher). Differential cell 
counts were determined using a microscope (Zeiss, West Germany) under oil immersion. 
Data are reported as % lymphocytes or neutrophils or the absolute number of 
lymphocytes and neutrophils (% x leukocyte count). 
51  
In Vitro DNA Fragmentation 
Thymocytes were cultured in vitro with 6-OHDA to determine if this chemical 
directly ind.uces DNA fragmentation. Single cell suspensions, prepared as described 
above, were pooled and cells were centrifuged at 300 x g for 1 0  minutes. After 
resuspending cells in RPMI media, a volume of 4.5 ml of thymocytes was added to 
individual 25-cm2 tissue culture flasks (Coming, Coming, NY). 6-OHDA was serially 
diluted in saline and added to culture flasks in 500 µl volumes to give the appropriate 
final concentration ( 1 .0 - 0.0 1  mM). For a positive control, thymocytes were cultured 
with a final concentration of 1 0  µM corticosterone dissolved in 1 % DMSO (final 
concentration of DMSO: 0.0 1 %). Culture flasks were loosely capped and cultured for 
three hours in 5% CO2 (thymocytes were gently resuspended every hour). The DNA 
fragmentation was assessed at the end of the culture period as described below. 
DNA Fragmentation Following In Vivo Treatment 
The level of DNA fragmentation in the thymus was quantitated using a procedure 
adapted from McConkey et al. ( 1990) and described by Fuchs and Pruett ( 1 993). 
Briefly, thymuses were prepared as described above from naive or treated mice. 
Thymocytes were cultured in a 4 ml volume of RPMI culture media in 12  x 7 5 snap cap 
tubes (Becton Dickinson, Lincoln Park, NJ) at 37°C in 5% CQi. Following 3 hours of 
culture, cells were washed two times with RPMI 1640 without phenol red (Sigma) then 
resuspended in 140 µ1 of RPMI 1640 without phenol red. Cells were subsequently 
transferred into 2 ml microfuge tubes (Baxter Scientific Products, McGaw Park, IL) and 
lysed with an 1 .4 ml of buffer containing 5 mM Tris, 20 mM EDTA and 0.05% Triton 
X- 100 (pH 8.0). Once vortexed, tubes were placed on ice for 10  minutes. Cell pellet 
and supernatant fractions were then separated by microfuge at 15,000 x g for 20 minutes. 
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This centrifugation pelleted the high molecular weight DNA and allowed for the low 
molecular weight DNA produced by the apoptotic process to remain in the supernatant 
fraction. The 1.4 ml volume of supernatant was transferred into a 12 x 75 tube for 
analysis while the pellet was resuspended with an additional 1.4 ml of buffer and 
carefully poured into a separate 1 2  x 75 tube. Samples were either analyzed 
immediately or stored overnight at 4°C. 
A bisbenzimide fluorescence assay (Labarca and Paigen, 1980) was utilized to 
determine the concentration of DNA present in the pellet and supernatant fractions for 
each thymus. A standard curve was prepared with O - 5 µg/ml DNA (calf thymus DNA -
Type 1; Sigma) for each study (linearity for this assay was determined up to 10 µg/ml). 
Aliquots of 100 µl of sample supernatants were added to assay tubes containing 2 ml 
sodium phosphate buffer (0.052 M) and 30 µl bisbenzamide (647 µg/ml; Sigma). Assay 
tubes were vortexed, then samples transferred to cuvettes (UV grade fluorometric ; A-
204X; Spectrocell, Oreland, PA) and read on a Shimadzu (Shimadzu Scientific 
Instruments, Columbia, MD) spectrofluorophotometer (355 nm excitation and 460 nm 
emission). Prior to analysis of the DNA in the pellet, a tissue tearor (Biospec Products, 
Bartlesville, OK) and a sonicator (Sonics & Materials Inc., Danbury, CT) were utilized 
to disrupt the pellets. Aliquots of 10 µl of pellet particles were added to assay tubes and 
read on the spectrofluorophotometer. The data are reported as the percent of total DNA 
present in supernatant 
Corticosterone As.say 
The concentration of corticosterone in mouse serum was determined by a 
radioimmunoassay kit (Diagnostic Products Corporation, Los Angeles, CA). One hour 
prior to sacrifice, water bottles and cage hoods were removed. Each mouse was brought 
separately into a necropsy room at various times following treatment with chemical or 
vehicle. Within a two minute time period, each mouse was anesthetized with CO2 and 
53 
blood collected by cardiac puncture with a 1 cc syringe and 23G 1 needle and placed into 
10 x 75 glass tubes. In all experiments, blood collection occurred between 08:00 and 
10:00 hours. Samples clotted at room temperature for at least one hour. Once clots were 
loosened with wooden applicator sticks, samples were left to continue clotting for an 
additional one to two hours at 4 °C. Following centrifugation at 800 x g for 10 minutes, 
serum was transferred into 2 ml microfuge tubes and samples subsequently microfuged 
at 8000 x g for 5 minutes at 4 °C to remove any residual erythrocytes. Serum was 
pipetted into fresh microfuge tubes and stored at -70°C until time of analysis. Data are 
reported as ng/ml corticosterone. 
Statistical analysis 
All studies were first analyzed using a one way analysis of variance (ANOV A). 
For the analyses which indicated a significant difference by the ANOV A, treatment 
groups were compared to vehicle controls using a Dunnett's two tailed test (Dunnett, 
1955). For the studies employing a blocking agent or receptor antagonist, a Duncan's 
Multiple Range analysis was performed on the corresponding treatment groups to 
determine the efficacy of the blocking agent. A Duncan's Multiple Range analysis was 
also performed to determine statistical significance in the time course studies. Results 
were considered significant with a p�0.05. Data are presented as the mean + standard 
error (S.E.). 
RESULTS 
Evaluation of the Effects of 6-0HDA and 5-0HDA on the Primary Antibody 
Forming Cell (AFC) Response 
The in vitro-in vitro lgM AFC response 
Researchers investigating the effect of 6-0HDA treatment on the AFC response 
have not assessed the direct effect of this chemical on immunocompetent cells. Studies 
were conducted to determine the cytotoxic potential of this neurotoxin and compare it to 
the non-neurotoxic congener, 5-0HDA. Direct addition of either 6-0HDA or 5-0HDA 
into cell cultures caused a dose-dependent suppression of the primary lgM AFC 
response to sRBC (Figure 12A). Assessment of cell viability following the five days of 
culture indicated that this suppression appears to be a function of decreased splenocyte 
viability (Figure 12B). Both 6-0HDA and 5-0HDA were cytotoxic to 
immunocompetent cells when present in sufficient concentration, although 6-0HDA 
exhibited approximately a 5-fold greater cytotoxicity than 5-0HDA. 
As cell viability in the studies above was only assessed at the end of the culture 
period, short term studies were conducted to determine at what point the viability of the 
cells started to decline. While there was no change in viability following one hour of 
culture, a significant decrease in cell viability was measured in the both the 6-0HDA­
and 5-0HDA-treated cultures after two hours of culture (Figure 13). As demonstrated 
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Figure 12. The in vitro-in vitro AFC response following addition of 6-OHDA or 5-OHDA. Naive mice were sacrificed, spleens asceptically removed and placed into antibody cultures with or without increasing concentration of 6-OHDA or 5-OHDA as described in Methods. A. The in vitro-in vitro primary AFC response to sRBC on day 
five of culture. The data are expressed as the mean lgM AFC/106 splenocytes ± S.E. of 4 culture wells/condition are representative of six independent experiments. B. The 
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Figure 1 3. Short tenn viability assessment following culture with 6-OHDA or 5-OHDA. 
Naive mice were sacrificed, spleens asceptically removed and placed into antibody 
cultures with VH (complete RPMI) or increasing concentrations of 6-OHDA or 5-
OHDA. The splenocyte viability was assessed at 1 ,  2, 4, or 24 hours of culture by 
propidium iodide exclusion and flow cytometric as described in Methods. The data are 
representative of two independent experiments and values are expressed as the mean % 
viability ± S.E. of 4 culture wells/condition. * *Significantly different from appropriate 
VH at p�0.0 1  as determined by Dunnett's test. 
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previously, 6-OHDA exhibits a greater cytotoxicity than 5-OHDA. The cytotoxicity 
produced by 6-OHDA occurs in a very short period of time, as the percentage of viable 
cells at the 24 hour time point was comparable to that observed following five days of 
culture with l mM 6-OHDA (Figure 12). 
The in vivo-in vitro lgM AFC response 
To determine if in vivo administration of 6-OHDA or 5-OHDA produced 
cytotoxicity in the spleen, the number and viability of splenocytes was evaluated at 1, 2, 
4, 24, and 48 hours following a single intraperitoneal injection of vehicle or 200 mg/kg 
of 6-OHDA or 5-OHDA. The cellularity of the spleen (Figure 14A) and splenocyte 
viability (Figure 14B) following 6-OHDA or 5-OHDA treatment did not display any 
significant differences from vehicle treatment at the time points that were evaluated. 
The primary lgM AFC response to sRBC was evaluated using splenocytes from 
treated mice which were sensitized in vitro. Previous studies conducted in this 
laboratory (Fuchs et al. , 1988) demonstrated that 6-OHDA treatment (200 mg/kg, i.p.) 
five days prior to sacrifice produced a more consistent suppression of the in vivo-in 
vitro AFC response than did 6-OHDA treatment two days before sacrifice. In the 
present investigation mice were treated with either vehicle (saline), or 200 mg/kg 6-
OHDA or 5-OHDA on five days and two days prior to sacrifice, and splenocytes from 
individual mice were placed into antibody cultures and sensitized in vitro with sRBC. 
On day five of the culture period, the AFC response of the splenocytes from 6-OHDA­
treated mice demonstrated a 50% suppression that was statistically significant at p�0.01 
(Figure 15). Splenocytes from 5-OHDA-treated mice generated an AFC response that 
was not different from vehicle treated mice. Viability assessment of the splenocytes 
from each mouse on the day of sacrifice found no difference between the vehicle (94 ± 
1 .2%), 5-OHDA (96 ± 0.3%), or 6-OHDA (93 ± 0.6%) treatment groups. Additionally, 
58 
A 
0 \,H 
1 00 
z a 5-0HDA w 90 w • 6-0HDA _, 
u, 80 --
co 70 
0 -
llC 60 -
u, _, _, 50 w 
40 'I '/ I I 
0 1 2 3 4 2 4  3 6  4 8  
TIME FOLLOWING TREATMENT (hours) 
B 
0 \,H 
a 5-0HDA 
• 6-0HDA 
97 
96 
► 95 -_, 
94 -
> 93 
'ii- 92 
91 
90 'I '/ I I 
0 1 2 3 4 2 4  3 6  4 8  
TIME FOLLOWING TREATMENT (hours) 
Figure 14. Splenocyte cell number and viability are not altered following 6-0HDA or 5-0HDA treatment. Mice were administered an intraperitoneal injection of VH (saline), 200 mg/kg 6-0HDA, or 200 mg/kg 5-0HDA at 1, 2, 4, 24, or 48 hours before sacrifice. 
Following removal of spleens, splenocyte suspensions were prepared and counted. A. Spleen cellularity. B. Splenocyte viability as determined by propidium iodide exclusion and flow cytometric analysis as described in Methods. Data are representative of two 
independent experiments and are expressed as the mean ± S.E. of 4 mice. 
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the splenocyte viability on day five of the culture was comparable across all treatment 
groups. 
In light of the fact that 6-0HDA produces a chemical sympathectomy, the 
suppression of the in vivo-in vitro AFC response following 6-0HDA treatment suggests 
that immunosuppression can result from depletion of catecholamines in the spleen. To 
determine if this 6-0HDA-induced effect could be reversed by restoring catecholamines 
in vitro, antibody cultures from vehicle, 6-0HDA or 5-0HDA treated mice were 
established and supplemented with 1 0  µM norepinephrine. The addition of 
norepinephrine did not reverse the 6-0HDA-induced suppression of the in vivo-in vitro 
AFC response and in fact appears to decrease the AFC response of the splenocytes 
obtained from all treatment groups (Table 1 ). 
The in vivo-in vivo IgM AFC response 
The primary IgM AFC response was determined in 6-0HDA- and 5-0HDA­
treated mice following in vivo sensitization with sRBC. Data previously reported by 
Fuchs and colleagues (1988) demonstrated that there was no significant suppression of 
the in vivo-in vivo AFC response when mice were treated either five days or two days 
prior to sensitization. Since 6-0HDA-induced immunosuppression was observed with 
the dosing paradigm for the in vivo-in vitro experiments, studies were initially conducted 
utilizing a similar paradigm whereby mice received vehicle or a dose of 200 mg/kg 6-
0HDA or 5-0HDA on five days and two days prior to sensitization. Four days post­
sensitization, the AFC response was evaluated and the data revealed that there was no 
difference between the three treatment groups (Table 2). When the dosing paradigm was 
modified such that mice were treated with vehicle or chemical on three days before and 
24 hours following sensitization, the in vivo AFC response of the 6-0HDA-treated mice 
demonstrated a significant suppression (Table 2). 
Table I 
Addition of Norepinephrine Does Not Reverse the 6-0HDA-lnduced 
Suppression of the In Vivo-In Vitro AFC Response 
Treatmenta IgM AFC/1()6 Splenocytesb 
VH 4512 ± 629 
5-OHDA 5528 ± 197 
6-OHDA 2406 ± 542** 
VH + NE 2970 ± 426# 
5-OHDA + NE 4091 ± 448 
6-OHDA + NE 1270 ± 496** 
aMice (n=4) received an intraperitoneal injection of VH (saline), 200 mg/kg 6-OHDA, or 200 mg/kg 5-OHDA on five days and two days prior to 
sacrifice. On the day of sacrifice, spleens were asceptically removed and 
placed into in vitro antibody cultures with or without the addition of 10 µM norepinephrine (NE). 
lrfhe number of IgM AFC/1()6 splenocytes was determined following five days of culture as described in Methods. Results are expressed as the mean 
± S.E. of 4 culture wells/treatment. Statistical analysis was determined by 
Duncan's Multiple Range test. **Significantly different from the 
appropriate control at p::5:0.01. #Significantly different from the 
corresponding treatment group at p::5:0.05. 
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Table 2 
The 6-0HDA-Induced Suppression of the In Vivo-In Vivo AFC 
Response is Dependent on the Time of Sensitization 
Treatment IgM AFC /1 ()6 Splenocytesa 
Anti�eo 48 hours followin� second treatmentb 
VH 
5-OHDA 
6-OHDA 
1352 ± 1 86 
1097 ± 28 
1126 ± 320 
Anti�eo 24 hours prior to second treatmentc 
VH 
5-OHDA 
6-OHDA 
1165 ± 162 
1061 ± 50 
732 ± 67* 
a1ne number of IgM AFC/106 splenocytes was determined four days 
post sensitization as described in Methods. Results are representative of 
two independent experiments and values are expressed as the mean ± 
S.E. *Significantly different from VH at p:5;0.01 as determined by 
Dunnett's test. 
hMice (n=4) received an intraperitoneal injection of VH (saline), 200 
mg/kg 6-OHDA, or 200 mg/kg 5-OHDA on five days and two days 
prior to in vivo sensitization with sRBC. 
CMice (n=4) received an intraperitoneal injection of VH (saline), 200 
mg/kg 6-OHDA, or 200 mg/kg 5-OHDA on three days prior to in vivo 
sensitization with sRBC. Mice received an additional dose of VH or 
chemical 24 hours following sensitization. 
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Additional studies evaluated the in vivo-in vivo AFC response in mice which 
received vehicle or chemical treatment on three days and thirty minutes prior to 
sensitization. The results revealed that both 6-OHDA and 5-OHDA treatment 
suppressed the in vivo-in vivo AFC response (Figure 16). This effect mediated by 5-
OHDA is the first data from the present investigation demonstrating a 5-OHDA-induced 
suppression in immune function following in vivo treatment 
Splenocyte Subpopulations in 6-0HDA- and 5-0HDA-Treated Mice 
In an attempt to further characterize the immunosuppression induced by 6-
OHDA treatment in vivo, the lymphocyte subpopulations in the spleen were analyzed 
following vehicle or chemical treatment on five days and two days prior to sacrifice. 
Utilizing immunofluorescent staining and flow cytometric analysis, splenocytes from 6-
OHDA-treated mice demonstrated a 38% decrease in the absolute number of CD4+ or T 
helper splenocytes (Figure 17 A), a 40% decrease in CD8+ or T suppressor/cytotoxic 
splenocytes (Figure 17B) and a 26% decrease in lg+ or B splenocytes (Figure 17C). 
Splenocyte subpopulations from 5-OHDA-treated mice did not differ from vehicle­
treated mice. 
6-0HDA and 5-0HDA Studies Utilizing the C3H Mouse Strain 
The in vitro-in vitro lgM AFC response with B6C3Fl or C3H splenocytes 
The C3H mouse strain has been reported to be highly sensitive to the effects of 6-
OHDA treatment (Livnat et al. , 1985). Studies were conducted to first evaluate if 
splenocytes obtained from C3H mice demonstrated an increased sensitivity to the effects 
of 6-OHDA or 5-OHDA when compared to splenocytes obtained from the B6C3Fl 
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Figure 16. Suppression of the in vivo-in vivo AFC response following 6-OHDA or 5-OHDA treatment Mice received an intraperitoneal injection of VH (saline), 200 mg/kg 
6-OHDA, or 200 mg/kg 5-OHDA on three days and 30 minutes prior to in vivo sensitization with sRBC. Four days post sensitization, spleens were removed and the 
primary AFC response determined as described in Methods. Data are representative of 
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Figure 17. Splenocyte subpopulations are decreased following 6-OHDA 
treatment. Mice (n=4) received an intraperitoneal injection of VH (saline), 
200 mg/kg 6-OHDA, or 200 mg/kg 5-OHDA on five and two days prior 
to sacrifice. On the day of sacrifice, spleens were removed, splenocyte 
suspensions prepared and subpopulations quantitated with monclonal 
antibodies and flow cytometric analysis as described in Methods. 
A. CD4+ splenocytes. B .. CD8+ splenocytes. C. lg+ splenocytes. 
Data are representative of three independent experiments and values are 
expressed as the mean absolute number of cells ± S.E. Statistical 
significance was determined by Dunnett's test. **Significantly different 
from VH at p�0.01 .  *Significantly different from VH at p�0.05. 
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mice. In vitro antibody cultures were established with each type of splenocyte and 
increasing concentrations of 6-0HDA or 5-0HDA and the in vitro-in vitro AFC 
response was quantitated on day five of culture. The results reveal that the AFC 
responses generated by the C3H splenocytes and the B6C3Fl splenocytes are not 
significantly different (Figure 18A and 18B). 
The primary AFC respome following in vivo treatment in CJH mice 
Studies were conducted to evaluate the in vivo-in vitro and in vivo-in vivo AFC 
response following 6-0HDA or 5-0HDA treatment in C3H mice. The dosing paradigms 
employed were identical to the B6C3Fl experiments described previously. The in vivo­
in vitro AFC response generated by C3H splenocytes did not demonstrate significant 
suppression following 6-0HDA treatment (Table 3). This is in contrast to the results 
obtained previously with the B6C3Fl mice. On the other hand, the in vivo-in vivo AFC 
response was significantly suppressed following either 6-0HDA or 5-0HDA treatment 
in C3H mice (Table 3). These data indicate that C3H mice exhibit either a similar or less 
sensitivity to the effects of 6-0HDA treatment when compared to B6C3Fl mice. 
Splenic subpopulatiom 
To determine the effect of 6-0HDA treatment on splenocyte subpopulations in 
C3H mice, the splenocytes from the in vivo-in vitro studies were stained with 
fluorescently conjugated monoclonal antibodies and analyzed by flow cytometric 
analysis. The results in Table 4 demonstrate that the lg+ splenocytes, but not the CD4+ 
or CD8+ splenocytes, were decreased by 6-0HDA treatment. Although not statistically 
significant, the 6-0HDA treatment does appear to decrease the leukocyte cellularity in 
the spleens of C3H mice. 
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Figure 18. Comparison of the in vitro-in vitro AFC response following addition of 6-
0HDA or 5-0HDA to cultures with C3H or B6C3Fl splenocytes. Naive mice were sacrificed, spleens asceptically removed and placed into antibody cultures with or 
without increasing concentration of 6-0HDA or 5-0HDA. On day five of culture the 
primary AFC response was determined as described in Methods. A. The primary AFC 
response generated by B6C3Fl splenocytes. B .  The primary AFC response generated 
by C3H splenocytes. The values are expressed as the mean AFC/culture calculated as % of control ± S.E. of 4 culture wells/condition. Statistical analysis by Duncan's Multiple 
Range test found no difference between the responses generated by the two mouse strains. 
Table 3 
The Primary AFC Response Following 6-0HDA 
or 5-0HDA Treatment in C3H Mice 
Tre atment 
VH 
5-OHDA 
6-OHDA 
In Vivo-In Vitro 
IgM AFC/106 
Splenocytesa 
1188 ± 96 
1486 ± 37 
871 ± 1 85 
In Vivo-In Vivo 
lgM AFC/106 
Splenocytesb 
883 ± 43 
617 ± 58* 
536 ± 74** 
aMice (n=4) received either an intraperitoneal inj ection of VH 
(saline), 200 mg/kg 6-OH DA, or 200 mg/kg 5-OHDA on fi ve 
days and two days prior to sacrifi ce. On the day of sacrifice, 
spleens were asceptically re moved, placed into in vitro antibody 
cultures, and t he number of l gM AFC/106 splenocytes 
determined as described in Methods. Results  are re presentat ive 
of tw o independent experiments and values are expressed as the 
mean ± S.E. of quadruplicate culture wells. 
bMice (n=4) received either an int raperitoneal inj ection of VH 
(saline), 200 mg/kg 6-OHDA, or 200 mg/kg 5-OHDA on three 
days and thirty minutes prior to in vivo sensit ization with sRB C. 
The number of IgM AFC/1 Q6 splenocytes was determined four 
days post sensit izat ion as described in Methods. Data  are 
expressed as the mean ± S.E. **Significant ly different from 
the appropriate cont rol at p�0.01 as determined by Dunnett' s 
test. *Signifi cantly different from the appropriate cont rol at 
p�0.05 as determined by Dunnett' s test 
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Table 4 
Splenic Alterations in C3H Mice Following 6-0HDA Treatment 
Splenocyte Subpopulationa 
Spleen Spleen 
Treatmentb Weight Cellularity (mg) (x 106) 
% CD4+ % Cos+ % Ig+ 
VH 105 ± 9.0 143 ± 1 3.4 17.7 ± 0.5 5.4 ± 0.3 46.8 ± 0.9 
(25.7 ± 3.2) (7.9 ± 0.8) (66.8 ± 10.0) 
5-OHDA 94 ± 4.0 129 ± 4.3 16.6 ± 1 .2 5.5 ± 0.3 42.0 ± 3.2 
(21 .4 ± 2. 1 )  (7. 1  ± 0.5) (53.9 ± 3.8) 
6-OHDA 98 ± 15.5 1 1 1  ± 13.9 1 8.2 ± 0.6 6.5 ± 0.3 37.8 ± 2.4* 
(20.4 ± 3. 1 )  (7.2 ± 0.8) (42.8 ± 7.8) 
aoetermined by immunofluorescent staining and flow cytometric analysis as described in Methods. 
Numbers in parentheses represent absolute cell number (cellularity x % positive). 
bMice (n=4) received an intraperitoneal injection of VH (saline), 200 mg/kg 6-OHDA, or 200 mg/kg 5-
OHDA on five days and two days prior to sacrifice. Results are representative of two independent 
experiments and values are expressed as the mean ± S.E. Statistical significance was determined by 
Dunnett's test. *Significantly different from appropriate VH at p�0.05. 
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Splenic Norepinephrine Levels Following 6-0HDA and 5-0HDA Treatment 
Levels of norepinephrine in the capsule and cellular portions of the spleen were 
quantitated in 6-OHDA and 5-OHDA treated mice. Treatment with 200 mg/kg 6-OHDA 
on five and two days prior to sacrifice produced a 9 1  % depletion of norepinephrine in 
the splenic capsule while the same dose of 5-OHDA produced a 49% depletion (Figure 
19A). In the splenic cell supernatant fraction, 6-OHDA depleted norepinephrine levels 
by 96% whereas 5-OHDA depleted nm-epinephrine by 48% (Figure 19B). The ability of 
the adrenergic uptake blocker, desmethylimipramine (DMI) to block the depletion of 
splenic norepinephrine following 6-OHDA and 5-OHDA treatments was evaluated. 
Although pretreatment with 25 mg/kg of DMI prevented the 6-OHDA-induced depletion 
of norepinephrine in the capsule and cell portions of the spleen, this dose of DMI was 
ineffective at blocking the 5-OHDA-induced depletion of splenic norepinephrine (Figure 
1 9A and 19B). Neither the DMI treatment alone or in combination with vehicle 
produced any changes in the level of splenic norepinephrine. 
Evaluation of Desmethylimipramine (DMI) Blockade of 6-0HDA-Induced 
Suppression of the Primary AFC Response 
In vitro-in vitro lgM AFC response 
To determine if DMI could directly block the 6-OHDA-induced suppression of 
the in vitro-in vitro AFC response, cultures were established with 0.3 or 1 .0 mM 6-
OHDA with or without a prior addition of 0. 1 or 1 .0 µM DMI. Quantitation of the AFC 
response on day five of culture revealed that DMI was not able to block this 6-OHDA­
induced suppression (Table 5). The AFC response of splenocytes treated with DMI was 
not significantly different from vehicle treated cultures. 
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Fi gu re 19. Depleti on of spleni c  norepinephrine following 6-OHDA or 5-OHDA 
treatment. Mice (n=4) re cei ved  an  intraperitoneal (i. p.) i njection of VH (saline), 200 
mg/kg 6-OHDA, or 200 mg/kg 5-OHDA, with or without a 30 minute prior i. p. i njection 
of 25 mg/kg desmethylimiprami ne (DMI) on fi ve days and two days before sacrifi ce. 
Spleens we re removed and the capsu le and ce ll portions prepared for norepinephri ne 
(NE) extracti on as  de scribed in  Methods. A. DMI blockade of 6-OHDA-induced  
depletion of NE in splenic capsu le. Values are expressed as  the mean pg concentration 
of NE per  mg splenic  capsule ± S.E. B. DMI blockade of 6-OHDA-induced  depletion 
of NE i n  splenic ce ll su pernatant fracti on. Value s are expre ssed a s  the mean pg 
concentration of NE per  mg splenocyte supernatant ± S.E. Data are representati ve of 
two independent expe ri ments. Statisti ca l  signi ficance was determined by Duncan' s 
Mu ltiple Range test. **Signifi cant ly di ffe rent from VH at pS0.01 . *Si gni fi cant ly 
di fferent from V H  at pS0.05. ##Signi ficant ly di fferent from corre spondi ng group at 
pS0.01 . 
Table 5 
Desmethylimipramine Does Not Block the 6-0HDA-Induced 
Suppression of the In Vitro-In Vitro AFC Response 
6-0HDA Concentration 
(mM) 
1.0 
1.0 
1.0 
0.3 
0.3 
0.3 
DMI Concentration 
(µM) 
0.1 
1.0 
0. 1 
1.0 
0.1 
1.0 
IgM AFC/106 Splenocytes 
1672 ± 131 
0 
0 
0 
0 
0 
0 
1849 ± 364 
1858 ± 219 
Splenocytes from naive mice were prepared and placed into in vitro antibody cultures in the presence of 6-OHDA (0.1 or 0.3 mM) with or without prior 
addition of 0.1 or 1.0 µM DMI (desmethylimipramine) as described in Methods. Data are expressed as the mean ± S.E. of 4 - 8 wells/condition. 
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In vivo-in vitro IgM AFC response 
The ability of DMI to block the 6-OHDA-induced suppression of the in vivo-in 
vitro AFC response was evaluated. Since the previous studies determined that 25 mg/kg 
DMI effectively blocked the depletion of splenic norepinephrine in 6-OHDA treated 
mice, this dose of DMI was injected thirty minutes prior to vehicle (saline), or 200 
mg/kg 6-OHDA or 5-OHDA on five days and two days prior to sacrifice. Splenocytes 
from individual mice were placed into in vitro antibody cultures, sensitized with sRBC, 
and the AFC response quantitated on day five of culture. The results reveal that the 6-
OHDA-induced suppression of the in vivo-in vitro AFC response was blocked when 
mice were pretreated with the adrenergic uptake inhibitor DMI (Figure 20). The DMI 
pretreatment did not significantly alter the response of the 5-OHDA treatment group and 
although there appears to be a slight suppression in the vehicle treatment group, this was 
not a consistent observation. 
In vivo-in vivo IgM AFC response 
Studies were conducted to determine how effective DMI was in blocking the 6-
OHDA- or 5-OHDA-induced suppression of the in vivo-in vivo AFC response. Mice 
were pretreated with 25 mg/kg DMI thirty minutes prior to administration of vehicle 
(saline), or 200 mg/kg 6-OHDA or 5-OHDA on three days and thirty minutes prior to 
sensitization with sRBC. Four days post-sensitization, the AFC response was evaluated. 
The results demonstrate that DMI blocked both the suppression of the in vivo-in vivo 
AFC response observed following either 6-OHDA or 5-OHDA treatment (Figure 21). 
DMI treatment alone or in combination with vehicle did not significantly alter the AFC 
response. 
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Figure 20. Desmethylimipramine b locks 6-OHDA-induced suppre ssion o f  the in v ivo-in 
vitro AFC re sponse. Mice were administe red an int rape ritoneal (i. p. )  i nje ction o f  V H  
( sali ne), 200 mg/kg 6-OHDA, or  200 mg/kg 5-OHDA, with or  without a 30 minute prior 
i.p. i njection o f  25 mg/kg desmethylimipramine (DMI) on five days and two days before 
sacrifice. On the day o f  sacrifice, spleens were asceptically re moved and placed  i nto 
antibody cu ltu res and the primary AFC re sponse dete rmined  on  day 5 o f  cu ltu re as 
described i n  Methods. Data  are representative o f  two i ndependent experi ment s  and 
values are expressed as the mean IgM AFC/106 splenocytes ± S.E. o f  4 mice evaluated 
in  tri plicate o r  quadruplicate. **Significantly differe nt from appropriate V H  at p:S;0.01 as 
determine d  by  Duncan' s Multiple Range test. 
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Figure 2 1 .  Desmethylimipramine blocks 6-OHDA- and 5-OHDA-induced suppression 
of the in vivo-in vivo AFC response. Mice received an intraperitoneal (i.p.) injection of 
VH (saline), 200 mg/kg 6-OHDA, or 200 mg/kg 5-OHDA, with or without a 30 minute prior i.p. injection of 25 mg/kg desmethylipramine (DMI) on three days and 30 minutes 
prior to in vivo sensitization with sRBC. Spleens were removed four days post 
sensitization and the primary AFC response quantitated as described in Methods. Data are representative of three independent experiments and are expressed as the mean IgM 
AFC/106 splenocytes ± S.E. of 4 mice evaluated in duplicate. Statistical significance 
was determined by Duncan's Multiple Range test. * *Significantly different from 
appropriate VH at p:S;0.01 .  ##Significantly different from corresponding treatment group 
at p:S;0.01 .  
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Splenocyte subpopulatiom 
Given the previous evidence that DMI pretreatment blocked the 6-OHDA­
induced suppression of the in vivo-in vitro and in vivo-in vivo AFC response, the ability 
of DMI to block the 6-OHDA-induced decreases in splenocyte subpopulations was also 
evaluated. Prior administration of 25 mg/kg DMI was not able to completely block the 
6-OHDA-induced decreases in splenocyte subpopulations (Table 6). 
Time of Sensitization Studies 
To investigate the mechanism of the 6-OHDA- and 5-OHDA-induced 
suppression of the in vivo-in vivo AFC response, studies were conducted to evaluate the 
effect of varying the time of sensitization with respect to administration of vehicle or 200 
mg/kg of the individual chemicals. Groups of mice were either sensitired thirty minutes 
following chemical, two hours prior to chemical, or two hours following chemical 
administration and the AFC response assessed four days later. In the 5-OHDA treatment 
group, a 46% suppression was observed when mice were sensitized 30 minutes 
following chemical treatment (Figure 22B). Although the AFC response of the 5-OHDA 
treatment group receiving antigen two hours prior to or two hours following treatment 
displayed a 23% and 26% suppression respectively, this was not statistically significant 
(Figure 22A and 22C). The AFC response demonstrated by the 6-OHDA treatment 
groups was significantly suppressed irrespective of the time of sensitization (Figure 22A, 
22B, 22C) and ranged from a 45% suppression when antigen was administered two 
hours following 6-OHDA treatment to 70% suppression when antigen was administered 
two hours prior to 6-OHDA treatment. The vehicle AFC response was consistent among 
all of the times for sensitization. 
Table 6 
Desmethylimipramine Does Not Block the 6-0HDA-Induced Decreases 
in Splenocyte Subpopulations 
Splenocyte Subpopulationa 
Treatmentb Spleen Weight Spleen Cellularity % CD4+ % CD8+ % Ig+ (mg) (x l06) 
VH 60.8 ± 3. 1 66.3 ± 5.7 22. 1 ± 0.6 10.3 ± 0.4 5 1 .4 ± 8. 1 
( 14.7 ± 1 .2) (6.8 ± 0.6) (39.0 ± 3.3) 
5-0HDA 58.8 ± 6.3 56.4 ± 5.7 22. 1 ± 0.7 10.2 ± 0.5 59.5 ± 0.6 
( 1 1 .9 ± 1 .0) (5.7 ± 0.4) (33.5 ± 3. 1 )  
6-OHDA 62.5 ± 10.8 49.4 ± 8.8 17. 1 ± 0.4** 9.7 ± 0.8 60.0 ± 1 . 1  
(8.5 ± 1 .7**)  (4.6 ± 0.5**) (29.4 ± 4.9) 
DMI 61 .0 ± 5.0 54.5 ± 6.0 2 1 . 1  ± 1 .2 9.7 ± 0.5 59.0 ± 0.5 
( 1 1 .3 ± 0.7) (5.2 ± 0.4) (32.2 ± 3.6) 
VH + DMI 64.0 ± 4. 1 54.9 ± 2.7 2 1 .5 ± 0.7 10.0 ± 0.5 59.7 ± 0.6 
( 1 1 .8  ± 0.6) (5.5 ± 0.3) (32.8 ± 1 .7) 
5-0HDA + DMI 54.5 ± 5. 1 56.2 ± 7.0 22.5 ± 0.4 1 1 .0 ± 0.2 58.6 ± 0.4 
( 1 2.7 ± 1 .6) (6.2 ± 0.8) (35.4 ± 3.7) 
6-OHDA + DMI 75.0 ± 3.5 55.6 ± 5.0 17.6 ± 1 .2** 8 .0 ± 0.6* 59.7 ± 1 .4 
(9.6 ± 0.4) (4.3 ± 0.2) (33. 1 ± 2.5) 
aoetennined by immunofluorescent staining and flow cytometric analysis as described in Methods. Numbers in parentheses 
represent absolute cell number (cellularity x % positive). 
bMice (n=4) received an intraperitoneal (i.p.) injection of VH (saline), 200 mg/kg 6-OHDA, or 200 mg/kg 5-OHDA with or 
without a 30 minute prior i.p. injection of 25 mg/kg desmethylimipramine (DMI) on five days and two days prior to sacrifice. 
On the day of sacrifice, spleens were removed and weighed and splenocyte suspensions were prepared for analysis. Results 
are representative of three independent experiments and values are expressed as the mean ± S .E. Statistical significance was 
detennined by Duncan's New Multiple Range test. * *Significantly different from appropriate VH at p�0.0 1 .  *Significantly 
different from appropriate VH at p�0.05. 
....J 
00 
79 
Figure 22. Time of sensitization alters suppression of the in vivo-in vivo AFC response following 6-OHDA or 5-OHDA treatment. Mice received an intraperitoneal (i.p.) injection of VH (saline), 200 mg/kg 6-OHDA, or 200 mg/kg 5-OHDA, three days prior 
to sensitization. On the day of sensitization, mice were sensitized with sRBC at various 
times relative to the second administration of chemical. A. Sensitization two hours prior to treatment. B. Sensitization 30 minutes following treatment. C. Sensitization two 
hours following treatment Spleens were removed four days post immunization and the 
primary AFC response quantitated as described in Methods. Data are representative of 
three independent experiments and values are expressed as the mean lgM AFC/106 splenocytes ± S.E. of 4 mice evaluated in duplicate. **Significantly different from VH 
at pg).01 as determined by Dunnett's test 
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Adrenergic Receptor Antagonist Experiments 
In an attempt to determine the mechanism of 5-OHDA-induced suppression of 
the in vivo-in vivo AFC response, studies were conducted to address the fact that 5-
OHDA administration causes a sympathomimetic event which may potentially result in 
a-adrenergic or 6-adrenergic receptor activation. The effect of blocking adrenergic 
receptors on this 5-OHDA-induced immunosuppression was evaluated. Mice were 
pretreated with either the a-adrenergic receptor antagonist phentolamine or the �­
adrenergic receptor antagonist propranolol thirty minutes prior to the administration of 
200 mg/kg 5-OHDA on three days and thirty minutes prior to sensitization with sRBC. 
The in vivo generated AFC response was assessed four days post-sensitization. Prior 
administration of phentolamine (Table 7), or propranolol (Table 8), in concentrations 
ranging from 0.3 - 30 mg/kg, did not block this 5-OHDA-induced suppression of the in 
vivo-in vivo AFC response. 
Determination of 6-0HDA-Induced Alterations in Peripheral Blood 
Studies were conducted to determine if 6-OHDA treatment produced alterations 
in the peripheral blood of mice. Blood was collected from mice utilized in the in vivo-in 
vivo dosing paradigm and was analyzed for various hematological parameters. While 
there were no significant changes in the erythrocyte number, hemoglobin or hematocrit, 
the leukocyte number did appear to be decreased (Table 9). Differential analysis 
revealed that there was a significant decrease in the percentage of lymphocytes and a 
corresponding increase in the percentage of neutrophils. The peripheral blood analysis 
of 5-OHDA-treated mice was not different from vehicle-treated mice. 
A time course was conducted to investigate this 6-OHDA-induced alteration 
peripheral blood lymphocytes and neutrophils. Peripheral blood differential analysis at 
Table 7 
Phentolamine Does Not Block the 5-0HDA-Induced Suppression 
of the In Vivo-In Vivo AFC Response 
Treatmenta 
VH 
5-OHDA 
VH + 30.0 mg/kg 
5-OHDA + 0.3 mg/kg 
5-OHDA + 3.0 mg/kg 
5-OHDA + 30.0 mg/kg 
lgM AFC/1()6 Splenocytesb 
1082 ± 58 
543 ± 152** 
1259 ± 79 
744 ± 51** 
611 ± 79** 
549 ± 124** 
aMice (n=4) received either no pretreatment or were injected intraperitoneally 
(i.p.) with 0.3, 3.0, or 30.0 mg/kg phentolamine thirty minutes prior to an i.p. 
injection of VH (saline) or 200 mg/kg 5-OHDA on three days and thirty minutes 
prior to in vivo sensitization with sRBC. 
hToe number of lgM AFC/1()6 splenocytes was determined four days post 
sensitization as described in Methods. Results are representative of two 
independent experiments and values are expressed as the mean ± S.E. 
**Significantly different from the appropriate control at p�0.01 as determined 
Duncan's New Multiple Range test 
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Table 8 
Propranolol Does Not Block the 5-0HDA-Induced Suppression 
of the In Vivo-In Vivo AFC Response 
Treatmenta 
VH 
5-OHDA 
VH + 30.0 mg/kg 
5-OHDA + 0.3 mg/kg 
5-OHDA + 3.0 mg/kg 
5-OHDA + 30.0 mg/kg 
lgM AFC/106 Splenocytesb 
1269 ± 61 
645 ± 1 15** 
1498 ± 1 06 
54 1 ± 88** 
907 ± 47** 
731 ± 47** 
aMice (n=4) received either no pretreatment or were injected intraperitoneally (i.p.) with 0.3, 3.0, or 30.0 mg/kg propranolol thirty minutes prior to an i.p. 
injection of VH (saline) or 200 mg/kg 5-OHDA on three days and thirty 
minutes prior to in vivo sensitization with sRBC. 
bToe number of lgM AFC/106 splenocytes was determined on day four post 
sensitization as described in Methods. Results are representative of two 
independent experiments and values are expressed as the mean ± S.E. 
**Significantly different from the appropriate control at p�0.0 1 as determined 
by Duncan's New Multiple Range test. 
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Table 9 
Analysis of Peripheral Blood Following 6-0HDA Treatment 
Peripheral Blood Differentiala 
RBC Hb Hct WBC Lymphocytes Neutrophils 
Treatmentb (106/mm3) (G/dL) (%) ( 1<>3/mm3) %C % 
VH 7.5 ± 0.5 17.6 ± 0.2 52.0 ± 0.7 10.6 ± 1 .4 83.8 ± 0.9 1 1 .5 ± 1 .2 
(8801 ± 1097) ( 1220 ± 204) 
5-01-IDA 7.6 ± 0.3 17.4 ± 0.2 53.3 ± 0.8 10.6 ± 1 .2 83.0 ± 1 .8 8.5 ± 1 .3 
(8722 ± 954) (901 ± 1 85) 
6-01-IDA 7. 1 ± 0.4 16.7 ± 0.7 49.0 ± 1 .7 8.5 ± 0.6 67.5 ± 3.5** 23.0 ± 2.7**  
(57 10 ± 527) ( 1941 ± 244) 
aoifferential analysis of eosinophil and monocyte populations was s;6%. 
bMice (n=4) received an intraperitoneal injection of VH (saline), 200 mg/kg 6-OHDA, or 200 mg/kg 5-OHDA on three days and 
thirty minutes prior to sensitization with sRBC (in vivo-in vivo paradigm). Four days post sensitization, blood was collected by 
retro-orbital bleed and hematological parameters evaluated as described in Methods. Results are representative of a single 
experiment and values are expressed as the mean ± S.E. Statistical significance was determined by Dunnett's test. 
**Significantly different from appropriate VH at ps;0.01 .  
CNumbers in parentheses represent absolute cell number per mm3 (cellularity x % positive). 
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12, 24, or 48 hours following a single injection of 200 mg/kg 6-OHDA revealed that at 
all time points measured there was a significant increase in the percentage of neutrophils 
and a decrease in the percentage of lymphocytes (Figure 23). 
Evaluation of the Effects of Chlorisondamine on the Primary AFC Response 
The in vitro-in vitro IgM AFC response 
As an alternative measure to remove the potential influence of the sympathetic 
nervous system on the humoral immune response, non-competitive ganglionic blocker 
chlorisondamine was utilized. Studies were first conducted to determine if this 
compound could directly effect the functional ability of immunocompetent cells. In 
vitro antibody cultures were established with increasing concentrations of 
chlorisondamine and the in vitro-in vitro IgM AFC response was evaluated on day five 
of culture. This in vitro generated primary AFC response was unaffected at 
concentrations of chlorisondamine ranging from 1 x lo-4 to l x lQ-10 M (Figure 24). 
The in vivo-in vivo lgM AFC response 
Having demonstrated that chlorisondamine does not directly influence the ability 
of immunocytes to generate antibody in vitro, studies were performed to evaluate the 
effect of chlorisondamine on the in vivo generated AFC response. In order to 
maintain a constant level of drug, mice were implanted with mini osmotic pumps on 
the day prior to in vivo sensitization with sRBC. The quantitation of the in vivo-in 
vivo AFC response four days post sensitization demonstrated that chlorisondamine 
treatment produced a dose-related suppression (Figure 25). While the 12 mg/kg/day 
dose of chlorisondamine produced only a slight suppression, the 20 mg/kg/day 
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Figure 23. Time course for peripheral blood alterations in 6-OHDA-treated mice. Mice (n=4) received an intraperitoneal injection of VH (saline) or 200 mg/kg 6-OHDA at 12, 
24 or 48 hours prior to sacrifice. Blood was obtained by cardiac puncture, prepared on slides and differential analysis performed as described in Methods. A. Time course for the increase in the percentage of neutrophils. B. Time course for the decrease in the 
percentage of lymphocytes. Results are representative of a single experiment and values 
are expressed as the mean % ± S.E. Statistical significance was determined by 
Dunnett's test. **Significantly different from appropriate VH at p::;;0.01. 
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Figure 24. The in vitro-in vitro AFC response following addition of chlorisondamine. 
Naive mice were sacrificed, spleens asceptically removed and placed into antibody cultures with either VH (complete RPMI) or increasing concentration of 
chlorisondamine ( lx l0-4 M to lx lQ-10 M) and the primary AFC response on day five of culture determined as described in Methods. The data are representative of four 
independent experiments and values are expressed as the mean lgM AFC/106 
splenocytes ± S.E. of 4 culture wells/condition. 
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Figure 25. Chlorisondamine treatment suppresses the in vivo-in vivo AFC response. 
Mice were surgically implanted with mini osmotic pumps containing either VH (saline) 
or chlorisondamine (12 or 20 mg/kg/day) one day prior to sensitization with sRBC. Four days post sensitization, the primary AFC response was quantitated as described in 
Methods. Data are expressed as the mean IgM AFC/spleen ± S.E. of 5 mice evaluated in 
duplicate. **Significantly different from VH at pg).01 as determined by Dunnett's test. 
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dose produced a statistically significant suppression of the in vivo-in vivo IgM AFC 
response. 
6-0HDA-Induced Thymic Alterations 
Weight, cellularity and thymocyte subpopulations 
Given the previous evidence that 6-OHDA treatment results in significant 
alterations in the spleen, studies were conducted to determine if this chemical also 
produces an affect in the thymus. The results revealed that mice treated with 200 mg/kg 
6-OHDA on day minus five and two prior to sacrifice demonstrated a 46% decrease in 
the thymic weight and an 65% decrease in thymic cellularity (Figure 26). This thymic 
atrophy was not observed when mice were treated with the non-neurotoxic congener 5-
OHDA. 
Immunofluorescent staining and flow cytometric analysis of thymocytes obtained 
from 6-OHDA-treated mice demonstrated that the absolute numbers of CD4+/CD8+, 
CD4-/CD8-, CD4+ and CDS+ thymocyte subpopulations were decreased 69%, 56%, 
50%, and 33% respectively (Figure 27). These alterations in thymocyte subpopulations 
were not observed following 5-OHDA treatment. 
Evaluation of thymic alterations in C3H mice treated with 6-OHDA 
demonstrated a 56% decrease in the thymic weight and an 76% decrease in thymic 
cellularity (Table 10). Similar to the results from the analysis of B6C3Fl thymocytes, 
the absolute numbers of CD4+/CD8+, CD4-/CD8-, CD4+ and CDS+ thymocyte 
subpopulations in C3H mice were decreased 80%, 70%, 55%, and 61 % respectively. 
The ability of the adrenergic uptake blocker DMI to block these 6-OHDA­
induced decreases in thymic weight, cellularity, and subpopulations was evaluated in 
B6C3Fl mice. The data in Table 11 demonstrates that DMI pretreatment effectively 
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Figure 26. 6-OHDA treatment decreases thymus wei ght and cellularity. Mice (n=4) 
were administe red an intraperitoneal injection of V H  (saline), 200 mg/kg 6-OHDA, or 
200 mg/kg 5-OHDA on five days and two days before sacrifi ce. On the day of sacrifice, 
thymuses  were removed and weight and ce llularity determine d. A. 6-OHDA-induced  
decrease in  thymic weight. B. 6-OHDA-induced decrease in  thymic  cellularity. Data 
are rep re se ntati ve of three i ndependent experiments  and are expre ssed as the mean ± 
S.E. ••Signi fi cantly di fferent from VH at pg).01 as determined by Dunnett' s test. 
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Figure 27. Thymocyte subpopulations in 6-OHDA-treated mice. Mice (n=4) were administered an intraperitoneal injection of VH (saline), 200 mg/kg 6-OHDA, or 200 
mg/kg 5-OHDA on five days and two days before sacrifice. On the day of sacrifice, thymuses were removed, thymocyte suspensions prepared and subpopulations 
quantitated with monoclonal antibodies and flow cytometric analysis as described in 
Methods. A .  CD4+/CD8+ thymocytes. B. CD4-/CD8- thymocytes. C .  CD4+ 
thymocytes. D. CD8+ thymocytes. Data are representative of three independent experiments and are expressed as the mean ± S.E. **Significantly different from VH at 
pg).01 as determined by Dunnett's test. *Significantly different from VH at p�0.05. 
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Table 10  
Thymic Alterations in  C3H Mice Following 6-OHDA Treatment 
Thymocyte Subpopulationa 
Treatmentb Thymus Weight Thymus Cellularity % CD4+/CD8+ % CD4+ % CDS+ % CD4-/CD8-(mg) (x 106) 
VH 54.3 ± 0.3 135.8 ± 6.0 80.9 ± 1 .0 10.7 ± 0.6 4.8 ± 0.3 3.5 ± 0.4 
( 1 10.3 ± 3.4) ( 1 3.9 ± 1 .2) (6.6 ± 0.9) (5.0 ± 0.9) 
5-OHDA 44.0 ± 1 .8 1 10.7 ± 3.3 78.3 ± 0.5 1 2.2 ± 0.8 4.9 ± 0. 1 4.6 ± 0.3 
(86.8 ± 2.6*) ( 1 3.5 ± 0.9) (5.4 ± 0.2) (5.0 ± 0.4) 
6-OHDA 23.8 ± 3.2** 32.4 ± 9.8** 63.0 ± 6.2* 2 1 .6 ± 3.0** 9.6 ± 2.0* 5.7 ± 1 .3 
(22. 1 ± 8. 1 **) (6.2 ± 1 .2**) (2.6 ± 0.4**) ( 1 .5± 0.2**) 
aoetermined by immunofluorescent staining and flow cytometric analysis as described in Methods. Numbers in parentheses 
represent absolute cell number (cellularity x % positive). 
bMice (n=4) received an intraperitoneal injection of VH (saline), 200 mg/kg 6-OHDA, or 200 mg/kg 5-OHDA on five days and 
two days prior to sacrifice. Results are representative of two independent experiments and values are expressed as the mean ± 
S.E. Statistical significance was determined by Dunnett's test. **Significantly different from VH at ps;0.01 .  *Significantly 
different from VH at ps;0.05. 
'° w 
Table 1 1  
Desmethylimipramine Blocks the 6-0HDA-Induced Decreases in the Thymus 
Thymocyte Subpopulationa 
Treatmentb Thymus Weight Thymus Cellularity % CD4+/CD8+ % CD4+ % cos+ % CD4-/CD8-(mg) (x106) 
VH 62.8 ± 2.8 152.2 ± 9.2 76. 1 ± 1 .0 14.5 ± 0.7 3.7 ± 0.2 5.7 ± 0.3 
( 1 15.7 ± 7.0) (22. 1 ± 1 . 8) (5.8 ± 0.5) (8.7 ± 0.6) 
5-OHDA 50.0 ± 5.4 1 19.3 ± 14.6 72.0 ± 0.8 16.3 ± 0.8 5.2 ± 0. 1 6.4 ± 0.2 
(85.9 ± 10.4*) ( 19.5 ± 3.0) (6.2 ± 0.7) (7.5 ± 0.7) 
6-OHDA 19.3 ± 1 .3** 25.4 ± 3.5** 48.3 ± 4.6** 30.7 ± 4.2** 1 1 .9 ± 0.9** 9.2 ± 0.5** 
( 12.6 ± 2.7**) (7.5 ± 0.5**) (2.9 ± 0.2**) (2.4 ± 0.5**) 
DMI 56.3 ± 5.8 135.7 ± 12.5 70.2 ± 1 . 1 *  1 8.0 ± 0.6 5.6 ± 0.3 6.2 ± 0.3 
(95.3 ± 9.0) (24.4 ± 2.5) (7.6 ± 0.8) (8.4 ± 0.6) 
VH + DMI 57.0 ± 5.3 145 . 1  ± 9.5 72.0 ± 0.9 16.5 ± 0.7 5.3 ± 0.2 6.3 ± 0.3 
( 104.4 ± 6.6) (24.0 ± 2.3) (7.7 ± 0.6) (9.0 ± 0.4) 
5-OHDA + DMI 64.7 ± 0.9 109. 1 ± 15.2 7 1 .3 ± 0.4 16.9 ± 0.3 5.2 ± 0.4 6.6 ± 0.2 
(78.0 ± 1 1 .0) ( 1 8.4 ± 2.6) (5.6 ± 0.7*) (7.2 ± 1 .0) 
6-OHDA + DMI 50.3 ± 3.7## 102.6 ± 5.2*## 70.9 ± 0.()6## 16.8 ± 0.3## 4. 1 ± 1 .4## 6.8 ± 0.3## 
(72.8 ± 3.8*##) ( 17 .3 ± 1 .  1 ##) (5.6 ± 0.3*##) (6.9 ± 0.3##) 
aoetermined by immunofluorescent staining and flow cytometric analysis as described in Methods. Numbers in parentheses 
represent absolute cell number (cellularity x % positive). 
bMice (n=4) received an intraperitoneal (i .p.) injection of VH (saline), 200 mg/kg 6-OHDA, or 200 mg/kg 5-OHDA with or 
without a 30 minute prior i.p. injection of 25 mg/kg desmethylimipramine (DMI) on five days and two days prior to sacrifice. 
On the day of sacrifice, thymuses were removed and weighed and thymocyte suspensions were prepared for analysis. Results 
are representative of three independent experiments and values are expressed as the mean ± S.E. Statistical significance was 
determined by Duncan's New Multiple Range test **Significantly different from appropriate VH at p�0.0 1 .  *Significantly 
different from appropriate VH at p�0.05. ##Significantly different from corresponding treatment group at p�0.01 .  
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blocked the 6-OHDA-induced decreases in thymic weight, cellularity, and thymocyte 
subpopulations. The DMI pretreatment did not effect the results of the either the VH or 
5-OHDA treatments. Although the DMI treatment alone appears to decrease the 
percentage of CD4+/CD8+ thymocytes, this was not a consistent observation. 
DNA fragmentation following in vivo treatment 
Studies were conducted to determine if the thymic atrophy observed following in 
vivo treatment with 6-OHDA was mediated by an increase in thymocyte DNA 
fragmentation. A time course study evaluated the thymic weight and cellularity and 
level DNA fragmentation in thymocytes at 12, 24, and 48 hours following a single 
administration of 200 mg/kg 6-OHDA. Neither the thymic weight nor cellularity were 
decreased at the 12 and 24 hour time points (Figure 28). However, at the 48 hour time 
point, the thymic weight demonstrated a 39% decrease and the cellularity of the thymus 
displayed a 57% decrease. Figure 29 demonstrates a time dependent increase in the 
level of DNA fragmentation in the murine thymus following 6-OHDA treatment. A 
maximal 2.7 fold increase over VH levels was measured 48 hours following 6-OHDA 
treatment. The level of thymic DNA fragmentation displayed by either the VH or 5-
OHDA treated mice did not differ from the naive control. Exogenous administration of 
corticosterone, the positive control for this assay, produced a 6-fold increase in the level 
of DNA fragmentation in the thymus. 
In vitro DNA fragmentation 
In order to evaluate the potential direct effect of 6-OHDA on thymocyte DNA 
fragmentation, in vitro culture studies were conducted. Thymocytes cultured for three 
hours in the presence of 0. 1 mM 6-OHDA demonstrated a 1 .3-fold increase in the level 
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Figure 28. Time course for the 6-OHDA-induced decrease in thymus weight and cellularity. Mice (n=4) received either no treatment (NA) or an intraperitoneal injection of VH (saline), 200 mg/kg 6-OHDA, or 200 mg/kg 5-OHDA at 12, 24, or 48 hours prior to sacrifice. The positive control group received a subcutaneous injection of 300 mg/kg corticosterone (CORT) 12 hours before sacrifice. On the day of sacrifice, thymuses were 
removed and weight and cellularity determined. A.  6-OHDA-induced decrease in thymic weight. B .  6-OHDA-induced decrease in thymic cellularity. Data are representative of two independent experiments and are expressed as the mean ± S.E. 
**Significantly different from appropriate VH at p�0.01 as determined by Duncan's 
Multiple Range test. * *Significantly different from appropriate VH at p�0.05 . 
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Figu re 29. Time cou rse fo r  thymic DNA fragmentation in 6-OHDA-tre ated mi ce. 
Mice (n=4) received  eithe r  no t reatment (NA) or an int raperitoneal injection of VH 
(saline), 200 mg/kg 6-OHDA, o r  200 mg/kg 5-OHDA at 12, 24, or 48 hou rs prior to  
sacrifice. The positive control group received a subcutaneous injection of 300 mg/kg 
corticosterone (CORT) 12 hours before s acrifice. On the day of sacri fi ce, thymuses were 
removed DNA fragmentation assessed as described in Methods. Data are re presentative 
of two independent expe riments and values are expressed as the mean % DNA in 
su pern atant ± S.E. **Si gni fi cantl y di ffe rent f rom appropri ate V H  at p�0.0 1 as 
determined by Duncan's Multiple Range test 
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of DNA fragmentation (Figure 30B). The level of DNA fragmentation in thymocytes at 
a concentration of (tOl mM 6-OHDA did not differ from VH, while a concentration of 
1 .0 mM 6-OHDA produced a 10.7-fold decrease in thymocyte DNA fragmentation. 
Assessment of viability at the end of the culture period revealed a 1 . 1 -fold decrease in 
thymocyte viability with 0. 1 mM 6-OHDA and a 2. 1 -fold decrease in thymocyte 
viability with 1 .0 mM 6-OHDA (Figure 30A). The positive control for thymocyte DNA 
fragmentation, 10  µM corticosterone, produced a 2. 1 -fold increase in apoptosis without 
altering the viability of the thymocytes. 
Chlorisondamine-Induced DNA fragmentation in the Thymus 
Given the evidence that in vivo treatment with the sympathetic neurotoxin 6-
OHDA results in an induction of DNA fragmentation in the thymus, studies were 
conducted to determine if the ganglionic blocker chlorisondamine also produced this 
effect in the thymus. The level of thymocyte DNA fragmentation was evaluated at 6, 1 2, 
24, and 48 hours following implantation with mini osmotic pumps containing 
chlorisondamine. Figure 3 1  demonstrates that chlorisondamine treatment does produce 
a time-dependent increase in the level of thymocyte DNA fragmentation which is 
maximal at the 24 hour time point and returns to vehicle levels by the 48 hour time 
point 
Corticosterone Studies 
Serum levels following 6-0HDA and 5-0HDA treatment 
In light of the fact that glucocorticoids are potent inducers of DNA fragmentation 
in thymocytes, the levels of corticosterone were measured at 1 2, 24, and 48 hours 
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Figure 30. In vitro DNA fragmentation and viability of thymocytes cultured with 6-OHDA. Thymuses were removed from naive mice, thymocyte suspensions prepared and 
pooled. Culture flasks were established (3 flasks/condition) with the thymocytes in the 
presence of either VH (RPMI), 6-OHDA (0.1, 0.1 or 1.0 mM), or CORT (10 µM). A. 
Thymocyte viability. The percentage of viable cells at the end of the culture period was 
assessed by propidium iodide exclusion and flow cytometric analysis as described in Methods. B .  DNA fragmentation in cultured thymocytes. The level of DNA fragmentation was determined as described in Methods. Data are reported as the % 
DNA in supernatant. Results are representative of three independent experiments and 
are expressed as the mean ± S.E. **Significantly different from appropriate VH at 
p�0.01 as determined by the Dunnett's test. 
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Figure 31. Time course for chlorisondamine-induced thymic DNA fragmentation. Mice (n=3 or 4) were surgically implanted with mini osmotic pumps containing either VH (saline) or chlorisondamine (20 mg/kg/day) at 6, 12, 24, and 48 hours prior to sacrifice. 
At the time of sacrifice, thymuses were removed and DNA fragmentation assessed as 
described in Methods. Data are expressed as the mean % DNA in supernatant ± S.E. Statistical significance was determined by Duncan's Multiple Range test. 
**Significantly different from appropriate VH at p�0.01. 
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following a single injection of either vehicle or 200 mg/kg 6-0HDA or 5-0HDA. 
Thesestudies revealed that while 5-0HDA treatment did not produce any alteration in 
the level of serum corticosterone at the time points measured, 6-0HDA treatment 
resulted in increased levels of this hormone at all time points measured (Figure 32). 
To further investigate the 6-0HDA-induced increase in serum corticosterone, 
levels of corticosterone were measured at 1, 3, 6, 9, and 12 hours following a single 
administration of chemical. Figure 33 demonstrates that there is a maximal IO-fold 
increase in serum corticosterone at the 1 hour time point While the levels of serum 
corticosterone following 6-0HDA treatment decrease after one hour, they remain 
elevated above VH levels throughout the 12 hour experiment. 
Since the previous studies revealed that DMI pretreatment was able to block the 
majority of the observed 6-0HDA-induced alterations, the ability of DMI to block the 6-
0HDA-induced increase in serum corticosterone was also evaluated. The corticosterone 
levels in treated mice were measured one hour following administration of chemical. 
The 6-0HDA-induced elevation in serum corticosterone was effectively blocked when 
mice were pretreated with DMI (Figure 34). Although the previous study which 
measured corticosterone at 12, 24, and 48 hours did not show an effect with 5-0HDA 
treatment, this study does reveal that there is a 5-0HDA-induced increase in 
corticosterone one hour after treatment. Furthermore, this increase in serum 
corticosterone is not blocked with the DMI pretreatment. 
Serum levels following chlorisondarnine treatment 
Having observed that 6-0HDA treatment produced an elevation in 
glucocorticoids, serum corticosterone levels were also determined in chlorisondamine­
treated mice. The level of corticosterone was measured at 6, 12, 24, and 48 hours 
following implantation of mini osmotic pumps. Figure 35 demonstrates that 
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Figure 32. Serum corticosterone levels following 6-OHDA or 5-OHDA treatment. Mice 
(n=4) received either no treatment (NA) or an intraperitoneal injection of VH (saline), 
200 mg/kg 6-OHDA, or 200 mg/kg 5-OHDA at 12, 24, or 48 hours prior to sacrifice. On 
the day of sacrifice, blood was obtained by cardiac puncture and serum was prepared and 
�ayed for corticosterone levels as described in Methods. Data are representative of two independent experiments and values are expressed as the mean level of corticosterone ± 
S.E. **Significantly different from appropriate VH at pS0.01 as determined by Duncan's Multiple Range test. 
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Fi gure 33. Short ti me cour se for t he 6-OHDA-induce d  e le vati on i n  serum 
corticosterone. Mice (n=3 ) receive d  either no treatment (NA) or an i ntraperitoneal 
i njection of V H  (saline )  or 200 mg/kg 6-OHDA at 1 ,  3, 6 ,  9, or 12 hours pri or to 
sacrifice. At the time of sacrifi ce, blood was obtained by cardi ac puncture and serum 
was prepared and assayed for corti costerone leve ls as described in Methods. Data are 
re presentati ve of two independent experiment s  and values are expre ssed  as t he mean 
level of corticosterone ± S.E. **Significantly different from appropriate V H  at pS0.01 as 
determine d  by Duncan' s Mu ltiple Range test. Significant ly different from appropriate 
VH at pS0.05. 
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Figure 34. Desmethylimipramine blocks the increase in serum corticoste rone following 
6-OH DA t reatme nt. Mice we re e it he r  u nhandle d  (NA) or administe red an  
intraperitoneal (i. p.) injection of VH (saline), 200 mg/kg 6-OH DA, or 200 mg/k g  5-
OHDA, w ith  or w ithout a 30 minute prior i. p. inject ion of 25 mg/kg desmethylipramine 
(DMI) at one hou r before sacrifice. At the t ime of sacrifice, b lood was obtained  by  
cardiac puncture and serum was prepared and a ssayed  fo r cort icoste rone leve ls a s  
de scribed in Methods. Data are repre sentative of two independent expe riments and 
values are expressed as the mean level of corticosterone ± S.E. Statist ical significance 
was determine d  b y  Duncan' s  Mu ltiple Range test. **Significantly different from 
appropriate VH at pg).01. ##Significantly different from corresponding t reatment group 
at pg).01. 
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Figure 35. Time course for the increase in serum corticosterone following chlorisondamine treatment. Mice (n=3 or 4) were surgically implanted with mini osmotic pumps containing either VH (saline) or chlorisondamine (20 mg/kg/day) at 6, 
12, 24, and 48 hours prior to sacrifice. At the time of sacrifice, blood was obtained by cardiac puncture and serum was prepared and assayed for corticosterone levels as described in Methods. Data are expressed as the mean level of corticosterone ± S.E. 
Statistical significance was determined by Duncan's Multiple Range test. 
**Significantly different from appropriate VH at p�0.01. 
107 
chlorisondamine treatment produces consistent elevation in serum corticosterone at all 
time points measured. 
Effects of exogenous cortic�terone administration 
To provide insight into the thymic alterations produced by corticosterone, 
experiments were conducted to assess the effect of exogenous administration of this 
glucocorticoid on the thymus. The kinetics of corticosterone-induced DNA 
fragmentation in the thymus were determined following a single oral gavage of 1 00  
mg/kg corticosterone. Corticosterone produced a time-dependent increase in thymocyte 
DNA fragmentation which was significant at 3, 6, and 9 hours after treatment (Figure 
36). This laboratory has previously determined that serum levels of corticosterone 
following an oral administration of 1 00  mg/kg corticosterone are approximately 2000 
ng/ml at 3 hours and return to baseline levels by 9 hours (unpublished observation). 
To verify that corticosterone is producing this effect through a receptor-mediated 
event, a dose response study was performed. The level of thymocyte DNA 
fragmentation was measured at nine hours following a dose of 5, 10, 25, 50, or 1 00  
mg/kg corticosterone. The data in Figure 37 clearly demonstrate the dose-responsive 
nature of corticosterone-induced DNA fragmentation in thymocytes. 
The thymocyte subpopulations from corticosterone-treated mice were analyzed to 
demonstrate that this hormone produces a selective depletion in the thymus. As 
expected, corticosterone selectively decreased the CD4+/CD8+ or immature population 
of thymocytes (Figure 38B). The profile of thymocyte subpopulations from 6-OHDA­
treated mice demonstrates that the CD4+/CD8+, CD4-/CD8-, CD4+, and CD8+ are 
decreased 89%, 72%, 66% and 50% respectively (Figure 38A). 
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Figure 36. Time course for corticosterone-induced thymic DNA fragmentation. Mice (n=4) received either no treatment (NA) or an oral gavage of VH (0.2% methylcellulose 
and 0.2% Tween 80 in Ringer's) or 100 mg/kg corticosterone (CORT) at 3, 6, or 9 hours 
prior to sacrifice. At the time of sacrifice, thymuses were removed and DNA 
fragmentation assessed as described in Methods. Data are expressed as the mean % 
DNA in supernatant ± S.E. **Significantly different from VH at p�0.01 as determined 
by Duncan's Multiple Range test. 
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Figure 37. Dose response of corticosterone-induced thymic DNA fragmentation. Mice (n=4) received either no treatment (NA) or an oral gavage of VH (0.2% methylcellulose 
and 0.2% Tween 80 in Ringer's) or 5, 10, 25, 50, or 100 mg/kg corticosterone (CORn at 9 hours prior to sacrifice. At the time of sacrifice, thymuses were removed and DNA fragmentation assessed as described in Methods. Data are expressed as the mean % 
DNA in supernatant ± S.E. **Significantly different from VH at p�0.01 as determined 
by Dunnett's test 
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Figure 38. Comparison of thymocyte subpopulations following 6-OHDA or corticosterone treatment. A. Thymocyte subpopulations following 6-OHDA treatment. 
Mice (n=4) were administered an intraperitoneal injection of VH (saline), or 200 mg/kg 6-OHDA on five days and two days before sacrifice. B. Thymocyte subpopulations 
following corticosterone treatment. Mice (n=4) were administered an oral gavage of VH (0.2% methylcellulose and 0.2% Tween 80 in Ringer's) or 100 mg/kg corticosterone 
(CORT) nine hours prior to sacrifice. At the time of sacrifice, thymuses were removed, thymocyte suspensions prepared and subpopulations quantitated with monoclonal antibodies and flow cytometric analysis as described in Methods. Data are expressed as 
the % of control of the absolute number of the indicated subpopulation. 
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RU-486 Blockade Studies with 6-0HDA 
Thymic DNA fragmentation 
Given the evidence that 6-0HDA treatment results in an increase in circulating 
levels of corticosterone, studies were conducted to determine if this elevation in serum 
corticosterone was mediating the 6-0HDA-induced increase in thymocyte DNA 
fragmentation. Experiments were first performed to assess the ability of the 
glucocorticoid antagonist, RU-486, to block corticosterone-induced DNA fragmentation 
in thymocytes. Figure 39 demonstrates that RU-486 effectively blocked the increase in 
DNA fragmentation following the administration of corticosterone. In addition, the RU-
486 treatment alone did not significantly alter the level of DNA fragmentation in the 
thymus. 
The ability of RU-486 to block the 6-0HDA-induced increase in thymocyte 
DNA fragmentation was assessed. When mice received RU-486 one hour prior to and 
12 hours following 6-0HDA treatment, the level of DNA fragmentation at 24 hours was 
partially blocked (Figure 40). A complete blockade of the 6-0HDA-induced DNA 
fragmentation in the thymus was only achieved when mice received RU-486 one hour 
prior to, and 9 and 18  hours following 6-0HDA treatment (Figure 40). 
In vivo-in vitro lgM AFC respome 
In light of the evidence that the 6-0HDA-induced increase in serum 
corticosterone was responsible for the thymic atrophy, studies were conducted to 
determine if this increase in glucocorticoids was also mediating the 6-0HDA-induced 
suppression of the in vivo-in vitro IgM AFC response. Using the in vivo-in vitro dosing 
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Figure 39. RU-486 blocks corticosterone-induced thymic DNA fragmentation. Mice 
(n=4) received either no treatment (NA) or were pretreated with an oral gavage of either 
VH (0.2% methylcellulose and 0.2% Tween 80 in Ringer's) or RU-486 ( 100 or 200 
mg/kg) one hour prior to receiving an oral gavage of either VH or 100 mg/kg 
corticosterone (CORT) at 9 hours prior to sacrifice. At the time of sacrifice, thymuses 
were removed and DNA fragmentation assessed as described in Methods. Data are 
representative of two independent experiments and values are expressed as the mean % 
DNA in supernatant ± S.E. Statistical significance was determined by Duncan's Multiple 
Range test ••Significantly different from VH at p�.01 .  ##Significantly different from 
corresponding treatment group at p�.01 .  
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Figure 40. Blockade of 6-OHDA-induced thymic DNA fragmentation by RU-486. Mice (n=4) received either no treatment (NA) or were pretreated with an oral gavage of either VH (0.2% methylcellulose and 0.2% Tween 80 in Ringer's) or RU-486 (200 mg/kg) one 
hour prior to receiving an intraperitoneal injection of either VH (saline) or 200 mg/kg 6-
OHDA. The 6-OHDA + RU-486 treatment group received additional doses of RU-486 
at either 1 2  hours or at 9 and 18  hours following 6-OHDA treatment. Mice were 
sacrificed 24 hours following 6-OHDA treatment, thymuses were removed and DNA 
fragmentation assessed as described in Methods. Data are representative of two independent experiments and values are expressed as the mean % DNA in supernatant ± S.E. Statistical significance was determined by Duncan's Multiple Range test. 
**Significantly different from VH at p�0.01 .  *Significantly different from VH at 
pg).05. ##Significantly different from corresponding treatment group at pg).01 .  
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paradigm, RU-486 was administered by oral gavage one hour prior to 6-0HDA 
treatment 
and every 12 hours thereafter until in vitro antibody cultures were established. Although 
RU-486 was able to block the corticosterone-induced suppression of the in vivo-in vitro 
AFC response, this antagonist was not able to block the 6-0HDA-induced 
immunosuppression (Figure 41). 
In vivo-in vivo lgM AFC response 
Studies were also conducted to evaluate the ability of RU-486 to block the 6-
0HDA-induced suppression of the in vivo-in vivo IgM AFC response. Using the in vivo­
in vivo dosing paradigm, RU-486 was administered by oral gavage one hour prior to 6-
0HDA treatment and every 12 hours thereafter until the in vivo generated AFC response 
was quantitated on day four post-sensitization. The results from these studies are 
identical to those observed for the in vivo-in vitro studies. RU-486 was able to block the 
corticosterone-induced suppression of the in vivo-in vivo AFC response, but this 
antagonist was not able to block the 6-0HDA-induced immunosuppression (Figure 42A 
and 42B). These studies also reveal that the corticosterone-induced suppression of the in 
vivo-in vivo AFC response is observed when the data are expressed as lgM AFC/spleen 
(Figure 42A) but not when the data are expressed as lgM AFC/106 splenocytes (Figure 
42B). However, 6-0HDA treatment suppresses the in vivo-in vivo AFC response 
irrespective of how the data are reported. 
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Figure 41. RU-486 does not block the 6-OHDA-induced suppression of the in vivo-in 
vitro AFC response. Mice (n=4) received an oral gavage of either RU-486 VH (0.2% 
methylcellulose and 0.2% Tween 80 in Ringer's) or RU-486 (200 mg/kg) one hour prior to and every 12 hours after receiving an intraperitoneal injection of VH (saline) or 200 
mg/kg 6-OHDA on five and two days prior to sacrifice. The CORT-treated mice received an oral gavage of either RU-486 VH or RU-486 (200 mg/kg) one hour prior to and 12 hours after receiving an oral gavage of 100 mg/kg CORT (corticosterone) at 24 hours prior to sacrifice. On the day of sacrifice, spleens were asceptically removed and 
placed into antibody cultures and the primary AFC response determined on day five of 
culture as described in Methods. Data are representative of two independent experiments 
and are expressed as the mean lgM AFC/1()6 splenocytes ± S.E. of 4 mice evaluated in quadruplicate. Statistical significance was determined by Duncan's Multiple Range test. 
**Significantly different from VH at pS0.01. ##Significantly different from 
corresponding treatment group at pS0.01. 
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Figure 42. RU-486 does not block the 6-OHDA-induced suppression of the in v ivo-in 
vivo AFC response. Mice received an oral gavage of either RU-486 VH (0.2% methyl­cellulose and 0.2% Tween 80 in Ringer's) or RU-486 (200 mg/kg) one hour prior to and every 12 hours after receiving an intraperitoneal injection of VH (saline) or 200 mg/kg 6-OHDA on three days and thirty minutes prior to in v ivo sensitization with sRBC .. The CORT-treated mice received an oral gavage of either RU-486 VH or RU-486 (200 
mg/kg) one hour prior to and every 12 hours after receiving an oral gavage of 100 or 150 mg/kg CORT (corticosterone) one hour prior to in v ivo sensitization with sRBC and 
every day thereafter. Four days post-sensitization, spleens were removed and the 
primary AFC response determined as described in Methods. Data are representative of two independent experiments and are expressed as A. the mean IgM AFC/spleen ± S.E. 
of 4 mice evaluated in duplicate or B. the mean IgM AFC/106 splenocytes ± S.E. of 4 mice evaluated in duplicate. Statistical significance was determined by Duncan's 
Multiple Range test. **Significantly different from VH at p�0.01. ##Significantly 
different from corresponding treatment group at p�.01. 
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RU-486 Blockade Studies with Chlorisondamine 
Body and organ weights 
As with the 6-0HDA studies, experiments utilizing RU-486 were conducted to 
address the potential role of corticosterone in chlorisondamine-induced alterations in the 
thymus and spleen. RU-486 was administered by oral gavage one hour prior to 
implantation with mini osmotic pumps containing chlorisondamine, and every 12 hours 
thereafter until the time of sacrifice. Table 12 demonstrates that RU-486 was effective at 
blocking the chlorisondamine-induced decreases in body weight, thymus weight, and 
spleen weight and cellularity. Unexpectedly, the RU-486 treatment significantly 
decreased the thymic weight in mice implanted with vehicle mini osmotic pumps. While 
administration of RU-486 in the vehicle treated mice did not significantly alter 
corticosterone levels, RU-486 in the chlorisondamine-treated mice produced a further 
elevation in the levels of circulating corticosterone. 
In vivo-in vivo lgM AFC response 
To determine if corticosterone was mediating the chlorisondamine-induced 
suppression of the in vivo-in vivo lgM AFC response, the ability of RU-486 to block this 
immunosuppression was evaluated. Although the previous data demonstrate that 
administration of RU-486 was able to block the decrease in splenic weight and 
cellularity, RU-486 was not able to block the chlorisondamine-induced suppression of 
the in vivo-in vivo lgM AFC response (Figure 43A and 43B). Similar to the 6-0HDA 
data, this immunosuppression observed following treatment with chlorisondamine is 
evident whether the data are expressed as lgM AFC/spleen or IgM AFC/1()6 splenocytes. 
Table 12  
RU-486 Blocks the Chlorisondamine-Induced Decreases in the Spleen 
Treattnenta Corticosterone b Body Weight Thymus Weight Spleen Weight Spleen Cellularity 
(ng/ml) (g) (mg) (mg) (x 106) 
VH + VHRu 168 ± 47 1 8.9 ± 0. 1 44.3 ± 4.3 77 ± 3.5 109 ± 1 1 .8 
CHL + VHRu 457 ± 95 15.7 ± 1 .0* 9.3 ± 1 .3** 39 ± 6. 1 ** 33 ± 1 1 .9** 
VH + RU-486 83 ± 40 18.6 ± 0.7 28.8 ± 0.8## 78 ± 4.0 103 ± 4.5 
CHL + RU-486 1 169 ± 1 3 1 ** 16.7 ± 1 .2 15.0 ± 1 .5** 67 ± 2.9## 76 ± 2.3## 
aMice were surgically implanted with mini osmotic pumps containing either VH (saline) or 20 mg/kg/day chlorisondamine 
(CHL) as described in Methods. Three hours prior to and every 12 hours thereafter, mice were administered either VHRu (0.2% methylcellulose and 0.2% Tween 80 in saline) or RU-486 (200 mg/kg) by oral gavage. On the day following 
implantation, mice were sensitired in vivo with sRBC. Four days post sensitization, blood and spleens were collected 
following sacrifice by CO2 overexposure. Data are expressed as the mean ± S.E. of 3-4 mice. Statistical significance was 
determined by Duncan's Multiple Range Test. 
* Significantly different from appropriate VH at p � 0.05. 
** Significantly different from appropriate VH at p � 0.0 1 .  
## Significantly different from corresponding treatment group which did not receive antagonist. 
hDetermined by radioimmunoassay as described in Methods. 
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Figure 43. RU-486 does not block the chlorisondamine-induced suppression of the in 
vivo-in vivo AFC response. Mice received an oral gavage of either RU-486 VH (0.2% methylcellulose or 0.2% Tween 80 in Ringer's) or RU-486 (200 mg/kg) one hour prior to and every 12  hours after surgical implantation of mini osmotic pumps containing either 
VH (saline) or CHL (chlorisondamine; 20 mg/kg/day). Four days post-sensitization, spleens were removed and the primary AFC response determined as described in Methods. Data are expressed as A. the mean lgM AFC/spleen ± S.E. of 3-4 mice 
evaluated in duplicate or B. the mean lgM AFC/106 splenocytes ± S.E. of 3-4 mice evaluated in duplicate. Statistical significance was determined by Duncan's Multiple 
Range test. **Significantly different from VH at p�0.01.  #Significantly different from 
corresponding treatment group at p�0.05. 
DISCUSSION 
The chemical sympathectomy produced by in vivo treatment with the adrenergic 
neurotoxin 6-hydroxydopamine (6-0HDA) is a useful method to explore the potential 
interactions between the sympathetic nervous system (SNS) and the immune system. 
Numerous investigators have reported that mice treated with 6-0HDA exhibit a 
suppression of the humoral immune response (Kasahara et al. , 1977; Hall et al. , 1982; 
Livnat et al. , 1985; Fuchs et al. , 1988). The central hypothesis of the present 
investigation is that the decreased antibody forming cell (AFC) response observed 
following 6-0HDA treatment is related to its ability to chemically sympathectomize 
mice. An important issue to consider when determining the relevance of 6-0HDA­
induced humoral immune suppression is whether or not 6-0HDA is directly cytotoxic to 
immunocompetent cells in vivo. The literature does not contain conclusive evidence to 
rule out the possibility of such a direct effect of 6-0HDA on lymphocytes. In an attempt 
to provide an adequate control for the potential in vivo cytotoxic effects on 
immunocompetent cells induced by 6-0HDA treatment, studies were conducted utilizing 
5-0HDA, a non-neurotoxic congener. Although 5-0HDA is also taken up into 
adrenergic neurons by the catecholamine uptake pump, and exhibits a false transmitter 
property (Tranzer and Thoenen 1967), this chemical does not lead to the destruction of 
adrenergic nerve terminals (Tranzer and Thoenen 1968). A comparison of the effects of 
direct addition of 6-0HDA or 5-0HDA to in vitro antibody cultures revealed that both 
6-0HDA and 5-0HDA will suppress the primary antibody response to sRBC when 
sufficient concentrations are present (Figure 12A). This suppression of the in vitro AFC 
response appears to be mediated by a decrease in culture viability (Figure 12B). While 
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both 6-0HDA and 5-0HDA are cytotoxic to immunocompetent cells when sufficient 
concentrations are present, these data reveal that 6-0HDA is 5-fold more cytotoxic than 
5-0HDA. Additional studies to assess culture viability at earlier time points 
demonstrated that (1) there was a significant decline in cell viability after two hours of 
culture with 1 mM concentration of either 6-0HDA or 5-0HDA and (2) the viability of 
the cultures at 24 hours was comparable to the viability at the end of the five day culture 
period (Figure 13). These results demonstrate that the cytotoxicity produced by both 6-
0HDA and 5-0HDA is a rapid event and this finding is consistent with the literature 
describing the greater capacity of 6-0HDA to generate reactive metabolites than 5-
0HDA (Kostrzewa and Jacobowitz, 1974). Due to the fact that 6-0HDA exhibits such a 
cytotoxic potential in vitro, a control for this cytotoxicity was desirable in order to 
accurately assess immune function following in vivo treatment. Had 5-0HDA 
demonstrated a similar level of cytotoxicity, it would have provided this important 
control. However, in light of these studies, it can be concluded that 5-0HDA does not 
completely control for the potential cytotoxicity produced by 6-0HDA in vivo. 
Thoenen and Tranzer ( 1968) provided evidence that a sufficiently high dose of 6-
0HDA is required in vivo in order for there to be an adequate sympathectomy. This 
finding may account for some of the inconsistencies found in data generated from 
different laboratories utilizing 6-0HDA in that ( 1 )  the dose of 6-0HDA was not 
sufficient to produce an adequate sympathectomy, or (2) the dose of 6-0HDA was too 
high and resulted in cytotoxicity. Due to the cytotoxic nature of 6-0HDA, it is essential 
that splenocyte viability be carefully assessed after in vivo treatment with this chemical. 
In the present study, splenocyte number and viability were not altered in the dosing 
paradigms employed for either the in vivo-in vitro or the in vivo-in vivo studies. 
Furthermore, splenocyte viability at 1, 2, 4, and 24 hours following a single 
administration of 200 mg/kg 6-0HDA or 5-0HDA demonstrated no difference between 
control and chemical treatments (Figure 14). 
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Given the evidence that the splenocyte viability is not compromised following in 
vivo treatment with 6-0HDA, the suppression of the in v ivo-in vitro generated primary 
AFC response is more meaningful. Previous studies conducted in this laboratory (Fuchs 
et al. , 1988) demonstrated that 6-0HDA treatment on five days prior to sacrifice 
produced a greater suppression (although not always statistically significant) of the in 
vivo-in v itro IgM AFC response to sRBC than did 6-0HDA treatment two days before 
sacrifice. The present investigation demonstrated 6-0HDA treatment on five and two 
days prior to sacrifice produced a consistent suppression of the in vivo-in vitro lgM AFC 
response (Figure 15). The absence of an effect in the 5-0HDA-treated mice suggests 
that the 6-0HDA-induced immunosuppression may be attributed to the destruction of 
adrenergic nerve terminals and the subsequent depletion of catecholamines. 
Studies conducted by Sanders and Munson (1984) demonstrated that 
norepinephrine added directly into antibody cultures produced an enhancement of the in 
vitro generated primary AFC response to sRBC. To address the possibility that the 6-
0HDA-induced suppression of the in vivo-in vitro AFC response was due to the absence 
of catecholamines, norepinephrine was added at the initiation of in vitro antibody 
cultures. This addition of norepinephrine did not reverse the 6-0HDA-induced 
suppression of the in vivo-in vitro AFC response (Table 1). This suggests that 
suppression of the in vitro generated primary AFC response following in vivo 6-0HDA 
treatment may be mediated by a functional impairment of the splenocytes from 6-
0HDA-treated mice. This dysfunction of immunocompetent cells may be attributed to 
the loss of neurotransmitters or other neuropeptides that would accompany the removal 
of the sympathetic influence in the spleen. 
To further investigate the effect of 6-0HDA treatment on the humoral immune 
response, the in vivo-in vivo AFC response to sRBC fol�owing treatment with 6-0HDA 
or 5-0HDA was assessed. Fuchs and colleagues (1988) demonstrated that there was no 
significant suppression of the in vivo-in vivo AFC response when mice were treated once 
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either five days, or two days, prior to sensitization. Since 6-OHDA-induced 
immunosuppression was observed with a five and two day dosing paradigm for the in 
vivo-in vitro experiments, studies were initially conducted utilizing a similar paradigm. 
Initial results found no effect on the in vivo generated primary AFC response when mice 
were immunized 48 hours following their second dose of chemical (Table 2). This result 
is consistent with Kasahara and coworkers (1977) who reported that 6-OHDA treatment 
suppressed the humoral immune response when the chemical was administered with 
antigen, or 48 hours after immunization, while no suppression was evident when mice 
were immunized two or seven days following 6-OHDA treatment. Cross and colleagues 
(1988) also determined that the suppression of antibody response induced by central 
administration of 6-OHDA was dependent upon the time of antigen sensitization with 
respect to chemical administration whereby no suppression occurred when mice were 
treated with 6-OHDA either 2 hours before, 24 hours after or 48 hours after sensitization. 
This suggests that the suppression induced by both central and peripheral administration 
of 6-OHDA is mediated by an event which alters the antibody response at an early time 
point. Evidence provided by Komeva and colleagues (1988) revealed that two minutes 
following an intravenous administration of sRBC, there is a significant increase in the 
splenic norepinephrine content Furthermore, the level of cAMP in the splenocytes was 
elevated ten minutes following antigen. Disruption of the adrenergic activity in the 
spleen during the initiation of the immune response in the spleen could therefore 
potentially alter the production of antibody. 
While investigating the effect of 6-OHDA or 5-OHDA on the in vivo-in vivo 
AFC response, it was demonstrated that when antigen was administered 24 hours prior 
to chemical treatment, the 6-OHDA, but not the 5-OHDA treatment produced 
immunosuppression (Table 2). However, when antigen was administered 30 minutes 
following chemical treatment, both 6-OHDA and 5-OHDA suppressed the in vivo-in 
vivo AFC response (Figure 16). This is the first evidence of a 5-OHDA-induced 
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immunosuppression. Administration of both 6-0HDA and 5-0HDA causes a transient 
sympathomimetic event in vivo whereby norepinephrine is displaced from the storage 
vesicles of adrenergic neurons. The piloerection, miosis, and tachycardia observed in 
the mice following chemical administration provided evidence that displacement of 
norepinephrine did occur. Due to this common factor shared by these two chemicals, 5-
0HDA appears to serve as an important control for studies investigating 6-0HDA­
induced effects on the immune response. This effect of chemical administration may be 
an important factor in studies investigating 6-0HDA-induced effects on the immune 
response and raises the possibility that the 6-0HDA-induced suppression of the in vivo­
in vivo AFC response may in fact be mediated in part by this sympathomimetic event. 
The suppression of the in vivo-in vitro and in vivo-in vivo primary AFC response 
observed following 6-0HDA treatment suggests that this chemical may alter the 
functional capacity of one or more immune cells required to generate an antibody 
response. Indeed, Fuchs and colleagues ( 1988) demonstrated that �-adrenergic receptors 
were upregulated on lymphocytes obtained from mice treated with 6-0HDA. Although 
antigen-specific T-cell function has been reported to be decreased by the sympathetic 
nervous system (Heilig et al. , 1993), there is no evidence in the literature indicating that 
immunosuppression induced by 6-0HDA treatment is mediated by an effect on a 
specific cell target. In an attempt to determine if there was a specific cell target 
mediating the 6-0HDA-induced suppression of the AFC response, splenocytes were 
analyzed for T helper cell (CD4+), T suppressor/cytotoxic cell (CDS+), and B cell (Jg+) 
surface marker expression. While 6-0HDA treatment caused a significant decrease in 
the absolute number of CD4+, CDS+, and lg+ lymphocytes in the murine spleen (Figure 
17), there appears to be a greater decrease in T lymphocytes, the splenocyte population 
which is closely associated with adrenergic nerve fibers in the PALS region of the 
spleen. The 5-0HDA treatment did not affect the splenic lymphocyte subpopulations. 
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These data reveal that in vivo administration of 6-0HDA can result in a loss of splenic T 
and B lymphocytes. 
Livnat and colleagues (1985) classified C3H mice as a murine strain which was 
sensitive to the effects of 6-0HDA-induced suppression of the in vivo AFC response. 
Initial studies were conducted to determine if C3H splenocytes exhibited a great 
sensitivity to the direct of effects of 6-0HDA than B6C3Fl splenocytes (Figure 18). 
Assessment of direct addition of 6-0HDA into culture demonstrated no significant 
difference in the in vitro-in vitro IgM AFC response between the two mouse strains. 
The in vivo-in vitro AFC response generated by 6-0HDA-treated C3H mice also did not 
demonstrate a greater sensitivity and in fact appeared to be less sensitive than the 
response generated by 6-0HDA-treated B6C3Fl mice (fable 3). Evaluation of the in 
vivo-in vivo lgM AFC response found the 6-0HDA- and 5-0HDA-induced suppression 
generated by C3H mice comparable to the response observed previously with B6C3Fl 
mice (Table 3). Although analysis of splenocytes from C3H mice treated with 6-0HDA 
demonstrated a comparable decrease in the percentage of lg+ splenocytes, no change 
was observed in the T lymphocyte population in the spleen (Table 4). It can be 
concluded from these studies that the C3H mouse strain does not demonstrate a greater 
sensitivity to the effects of 6-0HDA treatment. 
Within one hour following an intraperitoneal injection of 6-0HDA, the levels of 
norepinephrine from peripheral tissues are depleted (Laverty et al. , 1965; Malmfors and 
Sachs, 1968) and adrenergic neurons have lost their ability to generate action potentials 
(Haeusler, 1971). Fuchs and colleagues (1988) had previously determined that a single 
dose of 200 mg/kg 6-0HDA produces a 66% depletion of splenic cell fraction 
norepinephrine levels and a 96% depletion of splenic capsule norepinephrine levels. 
Furthermore, these scientists demonstrated that the 6-0HDA-induced depletion of 
norepinephrine in splenic capsule persists longer than the depletion of norepinephrine in 
the splenic cell fraction. Given the differences demonstrated between the capsule and 
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cell fractions of splenic norepinephrine, evaluation of norepinephrine in the splenic cell 
fraction following 6-OHDA treatment appears to be an important element in 
demonstrating an adequate removal of the sympathetic influence from 
immunocompetent cells. The various reports in the literature which have demonstrated 
that 6-OHDA depletes norepinephrine in the spleen (Williams et al. , 1981; Lyte, et al., 
1991) did not determine if the splenic cell fraction was sufficiently depleted of 
norepinephrine at the time immune parameters were analyzed. The present study 
demonstrated that splenic norepinephrine levels following two doses of 200 mg/kg 6-
OHDA were depleted 91 % in the capsule and 96% in the cell fraction (Figure 19A and 
19B). The norepinephrine levels in the spleens of mice treated with the non-neurotoxic 
congener, 5-OHDA, were depleted both in the capsule ( 49%) and in the cell fraction 
(48%). This 5-OHDA-induced depletion is consistent with the published results of 
Tram.er and Thoenen (1973) who demonstrated a significant depletion of norepinephrine 
in the heart 4 hours following 5-OHDA administration while normal levels were 
obtained 7 days after treatment This 5-OHDA-induced depletion may be the result of 
the transient displacement of norepinephrine from the storage vesicles of adrenergic 
nerve terminals which occurs upon administration of the chemical. Together with the 
data generated from the in vivo-in vitro AFC response (Figure 15), this result indicates 
that a 48% depletion of norepinephrine in splenic cell fraction does not impair the ability 
of splenocytes to generate a normal in vitro AFC response. It appears that a greater than 
50% depletion in splenic cell fraction norepinephrine is necessary in order for 
immunosuppression to occur. 
In an attempt to block the 6-OHDA-induced depletion of splenic norepinephrine, 
mice were pretreated with desmethylimipramine (DMI), a drug that blocks the amine 
transport system in adrenergic nerve terminals. In vitro studies assessing various uptake 
blockers have demonstrated that DMI was the most potent inhibitor of the catecholamine 
uptake pump with an IC50 in the nanomolar range (Iversen, 1965; Callingham, 1966). 
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Previou s reports in the literature (Stone et al. , 1964 ; Malmfors and Sachs, 1968; De 
Champlain, 1971 ) demonstrated that prior administration o f  25 mg/kg DMI prevented 
the 6-OHDA- induced de struction  o f  adrenergic neurons. Analy sis o f  spleens from 6-
OHDA-treated mice whic h  received DMI pre treatment revealed that norepinephrine 
levels were not significantly d ifferent from control mice in e ither the capsule or the cell 
fraction  (Figure 19A and 19B). The se da ta provide evide nce that  this DMI do sing 
paradigm does indeed e ffectively block the uptake and su bseque nt sympa thec tomy 
produced with 6-OHDA treatment. The DMI pretreatment was unable to block this 5-
OHDA- induced de ple tion  o f  splenic norepinephrine. A possible ex planation for the 
inabil ity o f  DMI to block the depletion  o f  splenic norepinephrine fo llowing 5-OHDA 
treatment may be attr ibu ted to 5-OHDA having a 25 - 50% higher affi nity for uptake 
sites  on  adrenergic neurons than 6-OHDA (Jonsson and Sachs, 1971 ). 
The ability o f  DMI to block the 6-OHDA- induced su ppre ssion  o f  the hu moral 
immune response was first evaluated in d irec t add ition  antibody cu ltures. Treatment o f  
cultures with DMI prior to the addition o f  6-OHDA did not block  the 6-OHDA- induced 
suppression o f  the in vitro-in vitro AFC re sponse (Table 5 ). This re su lt prov ide s 
ev idence that this immunosuppression observed in vitro was not a resu lt o f  lymphocy tes  
accumulating 6-OHDA by an uptake mechanism. 
In order to de termine if the uptake of  6-OHDA and the su bsequent destruc tion o f  
adrenergic nerve terminals was a prerequ isite for the 6-OHDA- induced suppression  o f  
the primary antibody response, the abil ity o f  DMI to block this immunosuppression was 
assessed. The literature has demonstrated that DMI pretrea tment blocks the 6-OHDA­
induced al teratio ns in murine T-cell mito genic ity (Ly te et al. , 1991 ), IgM antibody 
produc tion (Ackerman et al., 1991 ), and de layed hy persensitiv ity (Madde n et al. , 1989 ). 
In the present stud ies, DMI pretreatment blocked the 6-OHDA- induced su ppression o f  
both the in  vivo-in vitro and in vivo-in vivo lgM AFC re sponse (Figure 20 and Figure 
21 ). In addition  to provid ing spec ific ity to the 6-OHDA- induced suppression o f  the 
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humoral immune response, the DMI pretreatment demonstrates the lack of a direct effect 
of 6-0HDA in vivo since blockade of 6-0HDA uptake into the adrenergic neuron would 
result in an increased accumulation of the chemical extraneuronally. Although DMI 
pretreatment did not block the 5-0HDA-induced depletion of norepinephrine in the 
spleen, this adrenergic uptake inhibitor did function t-0 block the 5-0HDA-induced 
suppression of the in vivo-in vivo AFC response (Figure 21). Specifically, while the 5-
0HDA-treated mice which received DMI pretreatment still exhibited a 50% depletion in 
norepinephrine in the cell fraction of the spleen (Figure 19), this treatment group did not 
demonstrate a suppression in antibody production. This result suggests that a depletion 
of greater than 50% is required in order for there to be a measurable adverse effect on 
humoral immune response in the spleen. 
Since DMI was able to block the 6-0HDA-induced suppression of the primary 
antibody response, the effect of this pretreatment on the depletion of splenocyte 
subpopulations following 6-0HDA treatment was evaluated. These studies revealed that 
the 6-0HDA-induced decreases in absolute numbers of T and B lymphocyte 
subpopulations in the spleen was not blocked by DMI pretreatment (Table 6) and 
therefore may reflect a direct effect of 6-0HDA on splenocyte surface markers. 
Although 6-0HDA treatment appears to decrease the number of splenic T and B 
lymphocytes, the studies which demonstrated that DMI blocked the 6-0HDA-induced 
suppression of both the in vitro and in vivo AFC response indicate that the remaining 
splenocytes are still capable of producing an antibody response which does not differ 
from control. This therefore suggests that the suppression of the primary AFC response 
observed following 6-0HDA treatment cannot be attributed to this decrease in 
splenocyte subpopulations. 
In order to determine if the sympathomimetic effect caused by 6-0HDA and 5-
0HDA treatment mediates part of the observed suppression of the in vivo-in vivo AFC 
response, the time of sensitization with respect to chemical administration was 
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evaluated. These studies demonstrate that there is clearly a sensitization time dependent 
factor mediating the 5-OHDA-induced suppression of the in vivo-in vivo AFC response 
(Figure 22). Specifically, in order to obtain an significant immunosuppression with 5-
0HDA, antigen needed to be administered while mice were exhibiting signs of a 
sympathomimetic event (piloerection, miosis, and tachycardia). These results suggest 
that the 5-OHDA-induced displacement of norepinephrine from the adrenergic nerve 
terminals in the spleen may contribute to the observed immunosuppression. Although 
treatment with 6-OHDA significantly suppressed the in vivo-in vivo AFC response 
regardless of whether the mice received their second dose of chemical two hours prior 
to, thirty minutes following, or two hours following sensitization, the magnitude of the 
suppression ranged from 45% to 70%. 
Since 5-OHDA had been employed as a control for the sympathomimetic effect 
obtained from chemical administration, studies were conducted to assess the possible 
role of adrenergic receptor activation in mediating the 5-OHDA-induced suppression of 
the in vivo generated AFC response. Pretreatment with phentolamine, a non-selective a­
adrenergic receptor antagonist was unable to reverse the immunosuppression observed 
following 5-OHDA treatment (Table 7). These data suggest that activation of a­
adrenergic receptors does not mediate this observed suppression. Furthermore, these 
studies address the possibility that the spleen might be receiving less antigen following 
intravenous sensitization, and provide indirect evidence that an alteration in splenic 
blood flow is not involved in the 5-OHDA-induced immunosuppression. The possible 
role of the �-adrenergic receptor, the density of which is decreased following antigen 
sensitization (Fuchs et al. , 1988), was also investigated. Pretreating mice with 
propranolol, a non-selective �-adrenergic receptor antagonist, did not block this 5-
OHDA-induced suppression (Table 8). Collectively, these data suggest that neither an 
a-adrenergic nor a �-adrenergic receptor is mediating the 5-OHDA-induced 
immunosuppression. Given the evidence that adrenergic stimulation causes an efflux of 
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lymphocytes from the sp leen (Ernstrom and Sandberg, 1973; Murray et  al. , 1993), i t  i s  
possi ble that the suppre ssi on of the in vivo-in vivo AFC response fo llowing 5-0HD A  
treatment may be the re su lt of a decreased number of lymphocytes cau sed by the 
di sp lacement of norepinepbrine. Alternatively, the suppression of the in vivo generated 
primary  anti body re sponse observed  following treatment with  5-0HD A  may be 
mediated by the down regu lation of the �- adrenergic receptor re su lti ng from the re lease 
of norepi nephrine upon chemi cal admi ni str ati on. Since the abi lity of other more 
sele cti ve �- adrenergic receptor antagoni sts was not asse sse d, the possi bi lity of a �­
adrenergi c  re ceptor medi ated event cannot be completely ru led  out. W hether the 
mec hanism i s  through the efflux of sp lenocytes or the downregulation of �- adrenergic 
receptors, thi s  symp athomimeti c effect occurring within thirty minutes of sensiti zation 
appe ar s  to  compromi se the abi lity of the sp leen whi ch le ads to the observed 
immunosuppre ssion. These re sults  i ndi cate that there i s  i ndeed a comp lex interaction 
between the anti body response and the leve ls of norepinephrine in vivo. 
Researchers have not i nve sti gated the pote nti al e ffect of 6-0 HD A  on the 
peripheral blood. Hematological evaluation fo llowing 6-0HD A  treatment revealed  that 
whi le there were no si gni ficant effects on erythrocytes, there was a si gnificant decrease 
in  the percentage and absolute nu mber of circu lating lymphocytes and an increase in  
neutrophi ls (Table 9 ,  Figure 23 ). Thi s  i s  the first evi dence of a lymphopeni a and 
neutrophi li a  resulting from treatment with 6-0HDA. The fact that 5-0HD A  treatment 
did not produ ce an e ffect i n  the peripheral blood indi cate s that the 6-0HD A-induced  
alterations are not attributed to  the sympathomimeti c effect of chemical admini stration. 
The present stu die s investi gating the effects  of 6-0HD A  on the primary AFC 
re sponse indi cated a p ositi ve role of the SNS in humoral immu ne fu nction. To provide 
additional support for thi s  positi ve i nteraction, an alternati ve method for removing the 
i nflue nce of the symp athetic nervous  system was considered. Although Besedovsky and 
colleague s (1979)  produ ced a symp athectomy by surgi cal de nervati on in  rats, thi s  
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surgical manipulation in mice would be exceedingly difficult. The compound 
oh.lorisondamine (Ecolid) was chosen as an alternative method of removing the 
sympathetic influence in the spleen. Chlorisondamine is classified as a non-competitive 
ganglionic blocking agent which exhibits high affinity for cholinergic receptors in the 
ganglia and low affinity for cholinergic receptors located outside the ganglionic synapse 
(Van Rossum et al. , 1962). While researchers have utilized chlorisondamine to 
effectively block stress-induced alterations in brain neurotransmitter levels (Dunn and 
Welch, 1991), cocaine-induced stimulation of cardiac function (Tella et al. , 1992) and 
IL-I -induced suppression of NK activity and T-cell mitogenesis (Sundar et al. , 1990), 
assessment of immune function following chronic treatment with this compound has not 
been reported. The present investigation first determined that chlorisondamine did not to 
have a direct effect on the in vitro-generated lgM AFC response (Figure 24). Evaluation 
of the in vivo generated primary AFC reponse demonstrated that chronic treatment with 
chlorisondamine produced a dose-related suppression of the in vivo-generated IgM AFC 
response (Figure 25). These data are the first to demonstrate chlorisondamine-induced 
immunosuppression and further support the positive role of the autonomic nervous 
system (ANS) in the humoral immune response. 
Given the evidence that sympathectomy results in suppression of the primary 
AFC response to the T-dependent (thymus-dependent) antigen sRBC, it follows that 
evaluation of the effects of sympathectomy on the thymus would be pertinent to gain 
further insight into the mechanism through which this suppression in humoral immune 
fi.mction occurs. Thymic atrophy has been demonstrated following sympathectomy with 
reserpine (Drakoci and Jankovic, 1964). The literature investigating the effects of 
chemical sympathectomy with 6-OHDA has not clearly described thymic alterations 
following 6-OHDA treatment. While Hall and coworkers (1982) reported that 6-OHDA 
treatment produced atrophy of the thymus, Williams et al. (1981) reported that neonatal 
sympathectomy with 6-OHDA did not result in thymic atrophy. In the present 
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investigation, 6-OHDA treatment, but not 5-OHDA treatment, produced a significant 
decrease in the weight and cellularity of the thymus (Figure 26). Flow cytometric 
analysis revealed that this thymic atrophy was a result of decreases in all thymocytes 
(Figure 27). Similar results were obtained in thymuses of C3H mice (Table 10). These 
data demonstrate that the most immature CD4+/CD8+ thymocytes reflected the majority 
of the depletion and suggests a potential role of glucocorticoids since this population of 
thymocytes is extremely sensitive to depletion by this hormone (Cohen and Claman, 
1971). 
In an attempt to determine if the observed 6-OHDA-induced thymic atrophy was 
a consequence of sympathectomy, blockade studies were conducted with DMI. 
Pretreatment with this adrenergic uptake inhibitor effectively blocked all of the 6-
OHDA-induced decreases observed in the thymus (Table 11). These data demonstrate 
that the 6-OHDA-induced thymic atrophy requires the uptake of 6-OHDA into 
adrenergic nerve terminals. Furthermore, the results demonstrate a lack of a direct 
cytotoxic effect of 6-OHDA on thymocytes in vivo since blockade of 6-OHDA uptake 
into the adrenergic neuron would result in an increased accumulation of the chemical 
extraneuronally. 
Studies were conducted to investigate the mechanism through which this 6-
OHDA-induced thymic atrophy was occurring. The process of apoptosis is one 
mechanism through which cells can be eliminated (reviewed by Cohen and Duke, 1992). 
During this phenomenon, an activated endonuclease cleaves double standed DNA into 
180 - 200 base pair segments (Compton and Cidlowski, 1986). Studies conducted by 
Fuchs and Pruett (1993) have determined that the measurement of DNA fragmentation 
can be associated with the process of apoptosis. In this investigation, kinetic studies 
assessed the weight, cellularity and the level of DNA fragmentation in the thymus 
following a single treatment with 6-OHDA. While the decline in thymic weight and 
cellularity is not significant until 48 hours after treatment (Figure 28A and 28B), the 
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increased level of DNA fragmentation occurring in the thymus begins at 24 hours after 
treatment (Figure 29). These data demonstrate that there is an increase in DNA 
fragmentation which precedes the loss of cellularity in the thymus. This would be 
expected if apoptosis was the mechanism mediating this thymic atrophy. The level of 
DNA fragmentation appears to be maximal 48 hours following 6-OHDA administration 
as a subsequent measurement at 72 hours found no difference from control. Consistent 
with the absence of an effect of 5-OHDA treatment on the thymus, there was no 
measurable difference between the level of DNA fragmentation in 5-OHDA- and 
vehicle-treated mice. 
Since it had been demonstrated that in vivo administration of 6-OHDA increases 
thymic apoptosis, in vitro studies were conducted to ascertain if this induction of 
apoptosis may be attributed to a direct affect of this chemical on thymocytes. At 1 .0 
mM 6-OHDA, a concentration which decreased viability greater than 50% (Figure 30A), 
there was a significant decrease in DNA fragmentation (Figure 30B). This suggests that 
the decrease in DNA fragmentation may be attributed to the extensive necrosis produced 
by this chemical at this concentration. On the other hand, direct addition of 0.1 mM 6-
OHDA into culture produced a small increase in DNA fragmentation. However, this 
concentration of 6-OHDA also caused a significant decline in the viability of the 
thymocytes. Corticosterone, the positive control for apoptosis, produced a significant 
increase in DNA fragmentation but did not alter the viability of the thymocytes. If cell 
death was attributed solely to an apoptotic process, the cells would not exhibit a decrease 
in viability as measured by the uptake of propidium iodide due to the condensation of the 
nuclear chromatin and formation of apoptotic bodies. In light of this evidence, it would 
appear that the 0. 1 mM concentration of 6-OHDA can produce both DNA fragmentation 
and necrosis in thymocytes. This is supported by a recent report by Collins and 
colleagues ( 1992) which indicated that it is possible for DNA fragmentation and necrosis 
to occur simultaneously. Moreover, it has been suggested that apoptosis, in addition to 
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being a physiological phenomenon, is also a toxicological phenomenon (Anilkumar et 
al. , 1992). Indeed, hydrogen peroxide, one of the reactive metabolites produced by the 
oxidation of 6-OHDA, has been demonstrated at low concentrations (15 µM) to increase 
DNA fragmentation while high concentrations (600 µM) did not produce this result 
(Lennon et aL , 1990). 
The level of DNA fragmentation in the thymus following chlorisondamine 
treatment was assessed to determine if this method of sympathectomy also results in the 
induction of apoptosis. The profile for chlorisondamine-induced DNA fragmentation 
demonstrates a maximal increase at 24 hours following treatment (Figure 31). This 
result supports the evidence that sympathectomy can result in thymic hypoplasia which 
can be attributed to the increase in thymocyte DNA fragmentation. Interestingly, the 
maximal increase in DNA fragmentation produced by chlorisondamine occurred 24 
hours prior to the maximal increase observed with 6-OHDA. 
Determining the relative role of corticosteroids in drug, chemical, or stress 
induced immunosuppression is an important and necessary objective in order to 
understand the mechanism of a given immunosuppressive agent or event Indeed, Seyle 
(1936) demonstrated that adrenalectomy prevented the thymic atrophy resulting from 
such compounds as atropine, morphine and formaldehyde. In addition, Durant (1986) 
reported that in vivo, both glucocorticoids and catecholamines synergize to produce 
thymic alterations. Administration of various compounds in vivo, such as morphine (Sei, 
et al. , 1991), amphetamine (Pezzone et al., 1992), and gallium arsenide (Bums et al, in 
press), has been reported to elevate corticosterone levels. In light of the fact that the 
thymus is exquisitely sensitive to glucocorticoid-induced apoptosis, studies were 
conducted to determine if 6-OHDA treatment caused an increase in corticosterone. The 
literature has not fully explored the potential 6-OHDA-induced alterations in circulating 
corticosterone. A study conducted by Lippa and coworkers (1973) demonstrated that 
central administration of 6-OHDA produced a transient decrease in serum 
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corticosterone. However, Cuello and colleagues (1974) reported that 6-OHDA (100 
mg/kg, i.p.) produced a 4-fold increase in serum corticosterone at 24 hours in rats. The 
present investigation has demonstrated that the levels of serum corticosterone are 
elevated at 12, 24, and 48 hours following 6-OHDA treatment while treatment with 5-
OHDA did not produce any alterations in corticosterone at these time points (Figure 32). 
A maximal 10-fold increase in serum corticosterone was demonstrated one hour 
following administration of 6-OHDA (Figure 33). This result correlates well with 
Montanari and Stockham (1962) who reported that reserpine treatment in rats produced a 
maximal increase in plasma corticosterone one hour following administration. These 
data indicate that the sympathectomy produced with 6-OHDA causes an elevation in 
serum corticosterone. Given that different mouse strains are utilized in research and that 
there is a genetic regulation of glucocorticoid sensitivity (Tyan, 1979), this evidence of a 
6-OHDA-induced increase in serum corticosterone may provide further insight into the 
apparent discrepancies found in the 6-OHDA literature. 
To support the evidence that increased corticosterone is a consequence of 
sympathectomy, the ability of DMI to block this effect was evaluated. These studies 
demonstrate that DMI pretreatment does effectively block the 6-OHDA-induced increase 
in serum corticosterone (Figure 34). Interestingly, in this study 5-OHDA also elevated 
serum corticosterone - an effect that was not observed in earlier studies. This 5-OHDA­
induced increase in serum corticosterone suggests that the sympathomimetic effect of 
chemical administration, stimulates glucocorticoid release from the adrenal cortex at an 
early time point. This is consistent with the literature demonstrating that norepinephrine 
can stimulate the release of both CRF (Jones et al. , 1987) and ACTH (Labrie et al. , 
1987) in vitro. Furthermore, adrenergic innervation in the adrenal cortex has been 
described by Holzwarth and coworkers (1987). DMI did not block the 5-OHDA­
induced increase in serum corticosterone and supports the earlier data suggesting that 5-
OHDA may have a higher affinity than 6-OHDA for the uptake pump. 
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Although peripheral administration of 6-0HDA does not deplete the 
norepinephrine content in the adrenals (Thoenen and Tranzer, 1968), this chemical 
treatment can cause the release of epinephrine and norepinephrine from the adrenal 
medulla (Laverty et al. , 1965). In light of the possible association between 
cate.cholamine and glucocorticoid release (Krishnan et al, 1988), it would appear likely 
that treatment with 6-0HDA would also produce an elevation in corticosterone. 
However, since glucocorticoids are responsible for phenylethanolamine-N-methyl 
transferase (PNMT) induction in the adrenal medulla (Wurtman et al. , 1972), the 
maintained increase in serum corticosterone observed following 6-0HDA treatment may 
be linked to the reported compensatory increase in adrenal tyrosine hydroxylase and 
PNMT activity which occurs following 6-0HDA treatment (Mueller et al., 1969). 
Given the evidence that adrenaline synthesis can be reportedly regulated by ACTH and 
glucocorticoids (Wurtman and Axelrod, 1965) and sympathectomy produced by 
reserpine treatment results in increased ACTH secretion (Montanari and Stockham, 
1962), it is possible that the increase in serum corticosterone observed following 
sympathectomy with 6-0HDA is mediated by activation of the hypothalamic-pituitary­
adrenal (HPA) axis. Although peripheral administration of 6-0HDA does not cross the 
blood brain barrier, Cuello and coworkers (1974) suggested that the increase in 
corticosterone they observed following intraperitoneal administration of 6-0HDA was 
mediated by an increase in ACTH due to the decreased function of central adrenergic 
neurons inhibiting ACTH release. 
Evidence to support the activation of the HPA axis following sympathectomy 
was provided by the data demonstrating that serum corticosterone levels following 
chlorisondamine treatment were also increased (Figure 35). Although Slotkin and 
colleagues (1976) reported that chronic treatment with chlorisondamine increased 
adrenal cate.cholamine levels, the results from the present investigation demonstrating a 
chlorisondamine-induced elevation in serum corticosterone are the first known evidence 
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for increased glucocorticoids following treatment with this ganglionic blocker. The 
literature has reported that while decreased levels of plasma norepinephrine are 
maintained during chlorisondamine treatment (Kvetnansky et al., 1992), plasma 
dopamine 6-hydroxylase levels are unchanged (Reid and Kopin, 1975). Furthermore, 
tyrosine hydroxylase mRNA has been demonstrated to increase with chlorisondamine 
treatment (Schalling et al. , 1991 ). The literature has reported that chlorisondamine is 
able to block the CRF-induced increase in circulating catecholamines (Brown et al., 
1982; Fisher et al. , 1983) and reverse the effects of CRF on the cardiovascular system 
(Fisher and Brown, 1984) and metabolism (Koob, 1992). Romeo and colleagues ( 1990) 
demonstrated that plasma ACIB levels were significantly increased following superior 
cervical ganglionectomy whereas plasma CRF levels were not. In light of this study, it 
is possible that the observed increase in serum corticosterone observed following 
ganglionic blockade with chlorisondamine may not be mediated by the activation of the 
HPA at the level of the hypothalamus. Nevertheless, the data from the present 
investigation suggests that the peripheral ANS is an important mediator of HP A 
activation and that stimulation of this regulatory pathway can result from 
sympathectomy. 
Since it had been established that 6-OHDA treatment resulted in elevated serum 
corticosterone, studies were conducted to determine if the 6-OHDA-induced thymic 
atrophy was mediated by the increased levels of this glucocorticoid. Glucocorticoids are 
known to induce apoptosis through a receptor mediated event (Compton and Cidlowski, 
1986) and the present investigation demonstrated that corticosterone produces a time 
dependent increase in thymic DNA fragmentation (Figure 36) which is dose-responsive 
in nature (Figure 37). As with corticosterone, 6-OHDA treatment produced a profound 
depletion of the C4+/CD8+ thymocytes (Figure 38). The ability of the glucocorticoid 
receptor antagonist, RU-486, to block the 6-OHDA-induced DNA fragmentation in the 
thymus was therefore evaluated. RU-486 has previously been reported to successfully 
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block corticosteroid effects in vivo (Miller et al. , 199 1 ;  Pruett et al. , 1992; Bums et al. , 
in press). In the present studies RU-486 ( 100 or 200 mg/kg) completely blocked the 
corticosterone-induced increase in thymic DNA fragmentation in v ivo (Figure 39). 
Administration of RU-486 also completely blocked the 6-OHDA-induced apoptosis 
observed at 24 hours when the antagonist was administered one hour prior to, and 9 and 
18  hours following 6-OHDA administration (Figure 40). These studies also revealed 
that while a 12  hour dosing paradigm with RU-486 was effective for blocking 
corticosterone-induced suppression in the spleen (Bums et al. , in press), a 9 hour dosing 
paradigm is required to block the corticosterone induced apoptosis in the thymus. This 
finding may be related to the fact that only type II glucocorticoid receptors are found in 
the thymus whereas the spleen contains both type I (mineralcorticoid) and type II steroid 
receptors (Miller et al. ,  1990; Spencer et al., 199 1). 
Having determined that the 6-OHDA-induced increase in serum corticosterone 
was responsible for the thymic atrophy following treatment with this chemical, the 
possibility that this 6-OHDA-induced increase in glucocorticoids was mediating the 
suppression of the humoral immune response needed to be addressed. Moreover, the 
literature has reported that the immune response is modulated by circulating levels of 
corticosteroids (Cupps and Fauci, 1982) and that there is an inverse relationship between 
the in vitro AFC reponse and serum corticosterone levels (Gisler and Schenkel-Hulliger, 
197 1) .  The relative role of adrenal corticoids in 6-OHDA-induced suppression of 
humoral immunity has not been adequately investigated. Hall and coworkers ( 1982) 
reported that the 6-OHDA-induced decrease in antibody titers did not occur in 
adrenalectomized mice; however, these results did not demonstrate statistical 
significance. The present studies determined that while RU-486 treatment was able to 
block corticosterone-induced immunosuppression, this glucocorticoid receptor 
antagonist was not able to block the 6-OHDA-induced suppression of the in vivo-in v itro 
IgM AFC response (Figure 41)  or the in vivo-in vivo lgM AFC response (Figure 42A 
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and Figure 42B). This is the first conclusive evidence demonstrating that the 
suppression of the humoral immune response observed following 6-OHDA treatment is 
not mediated by glucocorticoids. Confirmation that suppression of humoral immune 
function observed following sympathectomy was independent of adrenal corticosteroids 
was provided by the data demonstrating that RU-486 was unable to block the 
chlorisondamine-induced suppression of the in vivo-in vivo IgM AFC response (Figure 
43). Although RU-486 was not able to block the suppression of the in vivo generated 
primary AFC response, this glucocorticoid antagonist was effective at blocking the 
decrease in splenic weight and cellularity (Table 12). RU-486 treatment appeared to 
block the chlorisondamine-induced decrease in body weight but not thymus weight. 
This supports earlier observations which indicated that in order to produce an effective 
blockade of glucocorticoid-induced thymic atrophy, RU-486 needs to be administered 
every 9 hours. The increased levels of serum corticosterone in chlorisondamine-treated 
mice which received RU-486 would be expected since negative feedback regulation 
would be interrupted with the antagonist 
The studies presented in this dissertation provide additional insight into possible 
mechanisms through which the SNS can influence immune function. A model depicting 
this potential modulation of immune function by the SNS is represented in Figure 44. 
Direct innervation of the spleen and thymus, in addition to adrenergic receptors on 
lymphocytes, provide potential pathways for neuroimmunomodulation. Regulation of 
immune function by the SNS can also be mediated by elevated levels of circulating 
glucocorticoids, either through the activation of the HP A axis, or by direct innervation of 
the adrenals. 
The key elements of this investigation demonstrate that 1) chemical 
sympathectomy with 6-OHDA suppresses both the in vivo-in vitro and in vivo-in vivo 
primary AFC response to sRBC; 2) blocking the ANS with the ganglionic blocker 
chlorisondamine produces a suppression of the in vivo generated primary AFC response 
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to sRBC; and 3) removal of the sympathetic influence either by 6-0HDA or 
chlorisondamine causes a subse,quent increase in circulating levels of corticosterone. 
Although it appears that activation of the SNS can negatively influence thymic 
regulation, the results from these studies suggest that the SNS is an important regulator 
of splenic antibody production and provides supporting evidence that the SNS is a 
positive modulator of the humoral immune response. 
SYMPATHETIC 
NERVOUS 
SYSTEM 
(?) (+) 
-
(-) 
Glucocorticoids ◄ 
Figure 44. Model for sympathetic modulation of immune function. 
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